<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">91044</article-id><article-id pub-id-type="doi">10.7554/eLife.91044</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.91044.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Neurophysiological trajectories in Alzheimer’s disease progression</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Kudo</surname><given-names>Kiwamu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5732-7229</contrib-id><email>kiwamu.kudo@jp.ricoh.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ranasinghe</surname><given-names>Kamalini G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4217-8785</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund13"/><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Morise</surname><given-names>Hirofumi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author"><name><surname>Syed</surname><given-names>Faatimah</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Sekihara</surname><given-names>Kensuke</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author"><name><surname>Rankin</surname><given-names>Katherine P</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Bruce L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Kramer</surname><given-names>Joel H</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Rabinovici</surname><given-names>Gil D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Vossel</surname><given-names>Keith</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Kirsch</surname><given-names>Heidi E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nagarajan</surname><given-names>Srikantan S</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7209-3857</contrib-id><email>srikantan.nagarajan@ucsf.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Biomagnetic Imaging Laboratory, Department of Radiology and Biomedical Imaging, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Medical Imaging Business Center, Ricoh Company Ltd</institution><addr-line><named-content content-type="city">Kanazawa</named-content></addr-line><country>Japan</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Memory and Aging Center,UCSF Weill Institute for Neurosciences, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Signal Analysis Inc</institution><addr-line><named-content content-type="city">Hachioji</named-content></addr-line><country>Japan</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043mz5j54</institution-id><institution>Department of Radiology and Biomedical Imaging, University of California, San Francisco</institution></institution-wrap><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/046rm7j60</institution-id><institution>Mary S. Easton Center for Alzheimer’s Research and Care, Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles</institution></institution-wrap><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Herrmann</surname><given-names>Björn</given-names></name><role>Reviewing Editor</role><aff><institution>Baycrest</institution><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Behrens</surname><given-names>Timothy E</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>28</day><month>03</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP91044</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-08-09"><day>09</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-08-09"><day>09</day><month>08</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.05.18.541379"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-10-09"><day>09</day><month>10</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.91044.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-01-15"><day>15</day><month>01</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.91044.2"/></event></pub-history><permissions><copyright-statement>© 2023, Kudo, Ranasinghe et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Kudo, Ranasinghe et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-91044-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-91044-figures-v2.pdf"/><abstract><p>Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Alzheimer's disease</kwd><kwd>magnetoencephalography</kwd><kwd>biomarkers</kwd><kwd>electrophysiology</kwd><kwd>functional connectivity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01AG062196</award-id><principal-award-recipient><name><surname>Nagarajan</surname><given-names>Srikantan S</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01NS100440</award-id><principal-award-recipient><name><surname>Nagarajan</surname><given-names>Srikantan S</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01DC017091</award-id><principal-award-recipient><name><surname>Nagarajan</surname><given-names>Srikantan S</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P50DC019900</award-id><principal-award-recipient><name><surname>Nagarajan</surname><given-names>Srikantan S</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P30AG062422</award-id><principal-award-recipient><name><surname>Miller</surname><given-names>Bruce L</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>K23AG038357</award-id><principal-award-recipient><name><surname>Vossel</surname><given-names>Keith</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>K08AG058749</award-id><principal-award-recipient><name><surname>Ranasinghe</surname><given-names>Kamalini G</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R21AG077498</award-id><principal-award-recipient><name><surname>Ranasinghe</surname><given-names>Kamalini G</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005595</institution-id><institution>University of California</institution></institution-wrap></funding-source><award-id>UCOP-MRP-17-454755</award-id><principal-award-recipient><name><surname>Nagarajan</surname><given-names>Srikantan S</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019250</institution-id><institution>John Douglas French Alzheimer's Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Vossel</surname><given-names>Keith</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000996</institution-id><institution>S. D. Bechtel, Jr. Foundation and Stephen Bechtel Fund</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Vossel</surname><given-names>Keith</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000957</institution-id><institution>Alzheimer's Association</institution></institution-wrap></funding-source><award-id>PCTRB-13-288476 made possible by Part the CloudTM</award-id><principal-award-recipient><name><surname>Vossel</surname><given-names>Keith</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000957</institution-id><institution>Alzheimer's Association</institution></institution-wrap></funding-source><award-id>AARG-21-849773</award-id><principal-award-recipient><name><surname>Ranasinghe</surname><given-names>Kamalini G</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001167</institution-id><institution>Larry L. Hillblom Foundation</institution></institution-wrap></funding-source><award-id>2015-A-034-FEL</award-id><principal-award-recipient><name><surname>Ranasinghe</surname><given-names>Kamalini G</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001167</institution-id><institution>Larry L. Hillblom Foundation</institution></institution-wrap></funding-source><award-id>2019-A-013-SUP</award-id><principal-award-recipient><name><surname>Ranasinghe</surname><given-names>Kamalini G</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution>Ricoh Company, Ltd.</institution></institution-wrap></funding-source><award-id>Research contract</award-id><principal-award-recipient><name><surname>Kirsch</surname><given-names>Heidi E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Event-based sequencing models for Alzheimer’s disease progression revealed that abnormal neural synchrony occurs during the earliest preclinical stages of the disease, preceding brain atrophy and cognitive decline.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>AD is a neurodegenerative disease characterized by amyloid-β (Aβ) and neurofibrillary tangles of abnormally phosphorylated tau (<xref ref-type="bibr" rid="bib13">DeTure and Dickson, 2019</xref>). Clinical and epidemiological studies have suggested that Aβ accumulation occurs early in the timeline of neuropathological changes in AD, likely preceding the accumulation of tau, and subsequent neurodegeneration and cognitive decline (<xref ref-type="bibr" rid="bib24">Jack et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Sperling et al., 2011</xref>). The neuropathological changes of AD are, therefore, described as a continuum, starting from the presymptomatic stage of proteinopathy and continuing to progress during the symptomatic stage with increasing stages of disease severity (<xref ref-type="bibr" rid="bib54">Sperling et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Jack et al., 2018</xref>). Transgenic mouse models of AD have shown that AD proteinopathy of Aβ and tau is associated with synaptic and circuit dysfunctions in neural networks (<xref ref-type="bibr" rid="bib7">Busche et al., 2008</xref>; <xref ref-type="bibr" rid="bib2">Ahnaou et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Busche et al., 2019</xref>). However, the temporal change in synaptic and circuit dysfunction during disease progression in patients with AD remains largely unknown.</p><p>Functional deficits in neural networks, especially in the presymptomatic stage, have attracted attention in recent years with the rapidly evolving landscape of plasma biomarkers of early detection and novel therapeutics showing the benefits of early intervention (<xref ref-type="bibr" rid="bib14">Dubois et al., 2016</xref>). In fact, abnormal neural oscillation synchrony has been reported not only in patients along the clinical spectrum of AD, including mild cognitive impairment (MCI) due to AD and AD-dementia (<xref ref-type="bibr" rid="bib28">Jeong, 2004</xref>; <xref ref-type="bibr" rid="bib17">Fernández et al., 2006</xref>; <xref ref-type="bibr" rid="bib57">Stam et al., 2006</xref>; <xref ref-type="bibr" rid="bib29">Koelewijn et al., 2017</xref>; <xref ref-type="bibr" rid="bib35">Nakamura et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Hughes et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Ranasinghe et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Meghdadi et al., 2021</xref>; <xref ref-type="bibr" rid="bib48">Schoonhoven et al., 2022</xref>) but also during the preclinical stages of AD (<xref ref-type="bibr" rid="bib35">Nakamura et al., 2018</xref>; <xref ref-type="bibr" rid="bib43">Ranasinghe et al., 2022a</xref>). Neuronal oscillations observed by noninvasive electrophysiological measures, such as electroencephalography (EEG) and magnetoencephalography (MEG), represent the synchronized activity of excitatory and inhibitory neurons and thus provide sensitive indices of altered neuronal and circuit functions in AD. As synaptic dysfunction is strongly associated with AD proteinopathy, altered neural oscillation synchrony may capture early functional deficits of neural networks even before clinical symptoms appear. However, it remains unknown which neurophysiological signature changes capture such deficits and the temporal evolution of these changes along the timeline of preclinical to MCI to AD dementia stages in clinical populations.</p><p>In this study, we investigated the trajectories of neurophysiological changes along the course of clinical progression of AD by examining long-range and local neural synchrony patterns in the resting brain. We hypothesized that frequency-specific long-range and local synchrony abnormalities in neuronal oscillations may precede both neurodegeneration and cognitive deficits. To examine the temporal relationship amongst altered neural synchrony, neurodegeneration, and cognitive deficits, we used data-driven disease progression models, specifically event-based sequencing models (EBM), which have been successfully used to predict AD progression from cross-sectional biomarker data (<xref ref-type="bibr" rid="bib18">Fonteijn et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Young et al., 2014</xref>; <xref ref-type="bibr" rid="bib67">Young et al., 2018</xref>). In an EBM, disease progression is described as a series of discrete events defined as the occurrence of a particular biomarker reaching a threshold abnormal value, and the estimated likelihood of the temporal sequence of events defines disease progression. Modifying conventional EBMs to find neurophysiological trajectories, we developed a robust EBM framework that is less sensitive to the thresholds for the determination of abnormality thereby resulting in an unbiased estimation of disease stage probability for each study participant.</p><p>Leveraging the high spatiotemporal resolution of MEG imaging, we considered two representative neuronal oscillatory synchrony metrics: amplitude-envelope correlation (AEC) and regional spectral power. The AEC and spectral power quantify long-range and local neural synchrony, respectively. Recent test-retest studies of MEG resting-state metrics have revealed that both metrics are highly reliable (<xref ref-type="bibr" rid="bib9">Colclough et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Wiesman et al., 2022</xref>). To evaluate the frequency specificity of neurophysiological trajectories, three canonical frequency bands, delta-theta (2–7 Hz), alpha (8–12 Hz), and beta (15–29 Hz) bands, were considered. For a metric of global cognitive ability, we used the mini-mental state examination (MMSE) score. Neurodegeneration, which is related to neuronal loss as well as synaptic loss and synapse dysfunction (<xref ref-type="bibr" rid="bib53">Selkoe, 2002</xref>; <xref ref-type="bibr" rid="bib56">Spires-Jones and Hyman, 2014</xref>), is detectable as brain atrophy on structural MRI, and therefore we evaluated neurodegeneration as loss of gray matter (GM) volume, specifically volume loss of the parahippocampal gyrus (PHG), extracted from individual T1 MRIs. We first deployed an Atrophy-Cognition EBM (AC-EBM) with only the neurodegeneration and cognitive decline measures, and then quantitatively examined metrics of long-range and local synchrony of neuronal oscillations corresponding to each estimated disease stage. Next, we deployed two separate Synchrony-Atrophy-Cognition EBMs (SAC-EBMs) which respectively included long-range or local neural synchrony measures along with PHG volume and global cognition, and investigated how the synchrony metrics stratify AD progression. Consistent with our hypothesis, we found that long-range and local neural synchrony in the alpha and beta bands, but not in the delta-theta band, becomes abnormal at the earliest preclinical stages of AD, preceding both neurodegeneration and cognitive deficits.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Participants</title><p>The present study included 78 patients who met National Institute of Aging–Alzheimer’s Association (NIA-AA) criteria (<xref ref-type="bibr" rid="bib32">McKhann et al., 2011</xref>; <xref ref-type="bibr" rid="bib3">Albert et al., 2011</xref>; <xref ref-type="bibr" rid="bib26">Jack et al., 2018</xref>) and 70 cognitively-unimpaired older adults. All participants were recruited from research cohorts at UCSF Alzheimer’s Disease Research Center (UCSF-ADRC). The diagnosis of AD patients was established by consensus in a multidisciplinary team. Among 78 AD patients, 20 had autopsy-confirmed AD neuropathology, other 41 patients were positive on the Aβ-PET scans, plus another nine patients showed cerebrospinal fluid (CSF) assays of amyloid and tau levels consistent with AD diagnosis. The remaining eight patients were clinically diagnosed, based on clinical evaluations and the characteristic pattern of cortical atrophy on MRI. Control participants were recruited from an ongoing longitudinal study of healthy aging at UCSF-ADRC. The eligibility criteria for cognitively normal controls included normal cognitive performance, normal MRI, and absence of neurological, psychiatric, or other major medical diseases. Forty-seven (out of 70) controls were evaluated with Aβ-PET and 8 were read as positive (39 as negative). The remaining 23 control participants were not evaluated with Aβ-PET. All participants underwent MMSE and a structured caregiver interview to assess the clinical dementia rating scale (CDR). All control participants were identified at CDR 0, indicating cognitively-unimpaired status on the CDR scale. Patients with AD ranged from 0.5 to 2 on the CDR scale. The results of demographic, functional, and cognitive assessments are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. Informed consent was obtained from all participants or their assigned surrogate decision makers. The study was approved by the Institutional Review Board of UCSF (UCSF-IRB 10–02245).</p></sec><sec id="s2-2"><title>MRI acquisition and analyses</title><p>Structural brain images were acquired using a unified MRI protocol on 3T Siemens MRI scanners (MAGNETOM Prisma or 3T TIM Trio) at the Neuroscience Imaging Center (NIC) at UCSF, within an average of 1.05 years (range: -6.91–0.78) and 0.29 years (range: -2.13–1.29) of the MEG evaluation for controls and patients, respectively. The acquired MRI was used to generate the head model for source reconstructions of MEG sensor data and to evaluate GM volumes. The region-based GM volumes corresponding to the 94 anatomical regions included in the Automated Anatomical Labeling 3 (AAL3) atlas (<xref ref-type="bibr" rid="bib45">Rolls et al., 2020</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) were evaluated using the Computational Anatomy Toolbox [CAT12 version 12.8.1 (1987)] (<xref ref-type="bibr" rid="bib19">Gaser et al., 2022</xref>), which is an extension of SPM12 (<xref ref-type="bibr" rid="bib38">Penny et al., 2011</xref>); the regional GM volumes were calculated using the morphometry pipeline implemented in CAT12 with default parameters. The total intracranial volume (TIV), the sum of all segments classified as gray and white matter, and CSF, was also calculated for each subject.</p></sec><sec id="s2-3"><title>Resting-state MEG</title><sec id="s2-3-1"><title>Data acquisition</title><p>Each participant underwent 10–60-min resting-state MEG at the UCSF Biomagnetic Imaging Laboratory (BIL). MEG was recorded with a 275-channel full-head CTF Omega 2000 system (CTF MEG International Services LP, Coquitlam, British Columbia, Canada). Three fiducial coils for nasion and left and right preauricular points were placed to localize the position of the head relative to the sensor array and later co-registered with individual MRI to generate an individualized head shape. Data collection was optimized to minimize head movements within the session and to keep it below <inline-formula><mml:math id="inf1"><mml:mrow><mml:mn>0.5</mml:mn><mml:mo>⁢</mml:mo><mml:mi>cm</mml:mi></mml:mrow></mml:math></inline-formula>. For analysis, a 10-min continuous recording was selected from each subject lying supine and awake with the eyes closed (sampling rate <inline-formula><mml:math id="inf2"><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>600</mml:mn><mml:mo>⁢</mml:mo><mml:mi>Hz</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>). From the continuous recordings, we further selected a 1-min continuous segment with minimal artifacts (i.e. minimal excessive scatter at signal amplitude) for each subject.</p></sec><sec id="s2-3-2"><title>Pre-processing</title><p>Each 1-min sensor signal was digitally filtered using a bandpass filter of <inline-formula><mml:math id="inf3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>0.5</mml:mn></mml:mstyle></mml:math></inline-formula>–<inline-formula><mml:math id="inf4"><mml:mrow><mml:mn>55</mml:mn><mml:mo>⁢</mml:mo><mml:mi>Hz</mml:mi></mml:mrow></mml:math></inline-formula>. The power spectral density (PSD) of each sensor signal was computed, and artifacts were confirmed by visual inspections. Channels with excessive noise within individual subjects were removed prior to the next process. When environmental noises larger than a few pT/<inline-formula><mml:math id="inf5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msqrt><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">z</mml:mi></mml:mrow></mml:msqrt></mml:mstyle></mml:math></inline-formula> were observed around the 1–5-Hz range in a PSD, the dual signal subspace projection (DSSP) (<xref ref-type="bibr" rid="bib52">Sekihara et al., 2016</xref>) with the lead field vectors computed for each individual subject’s head model was applied to the filtered sensor signal for the removal of environmental noise. As a parameter, we chose the dimension of pseudo-signal subspace μ as 50. DSSPs were needed to be applied to 13 of the total 148 subject signals. For the 13 data, the resulting dimension of the spatio-temporal intersection, that is, the degree of freedom to be removed, was 3 or 4. We also applied a preconditioned independent component analysis (ICA) (<xref ref-type="bibr" rid="bib1">Ablin et al., 2018</xref>) to the signal to identify cardiac components and remove them. In each data set, one or two clear cardiac ICA-component waveforms with approximately 1 Hz rhythms were observed, which were easily identified by visual inspections.</p></sec><sec id="s2-3-3"><title>Atlas-based source reconstruction</title><p>Isotropic voxels (5 mm) were generated in a brain region of a template MRI, resulting in 15,448 voxels within the brain region. The generated voxels were spatially normalized to individual MRI space, and subject-specific magnetic lead field vectors were computed for each voxel with a single-shell model approximation (<xref ref-type="bibr" rid="bib36">Nolte, 2003</xref>). The voxels for each subject were indexed to 94 cortical/sub-cortical regions included in the AAL3 atlas.</p><p>Array-gain scalar beamformer (<xref ref-type="bibr" rid="bib49">Sekihara et al., 2004</xref>) was applied to the 60 s cleaned sensor time series to obtain source-localized brain activity at the voxel level, i.e., voxel-level time courses. Lead field vectors were normalized to avoid the center-of-the-head artifact, and a generalized eigenvalue problem was solved to determine the optimal source orientation (<xref ref-type="bibr" rid="bib50">Sekihara and Nagarajan, 2008</xref>). The beamformer weights were calculated in the time domain; a data covariance matrix was calculated using a whole 60 s time series, and a singular value truncation (threshold of <inline-formula><mml:math id="inf6"><mml:mrow><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:msup><mml:mo>×</mml:mo></mml:mrow></mml:math></inline-formula> maximum singular value) was performed when inverting the covariance matrix. Ninety-four regional time courses were extracted with alignment with the AAL3 atlas by performing a principal component analysis (PCA) across voxel-level time courses within each of the regions and taking a time course of the first principal component. These pre-processing and source reconstructions were performed using in-house MATLAB scripts utilizing Fieldtrip toolbox functions (<xref ref-type="bibr" rid="bib37">Oostenveld et al., 2011</xref>). We also used BrainNet Viewer toolbox (<xref ref-type="bibr" rid="bib65">Xia et al., 2013</xref>) to obtain brain rendering images of regional MEG metrics and GM atrophy.</p></sec><sec id="s2-3-4"><title>MEG resting-state metrics</title><p>Based on the regional time courses derived from MEG, we evaluated two measures of neural synchrony: the amplitude-envelope correlation (AEC) and spectral power, which describe long-range and local neural synchrony, respectively. Three canonical frequency bands were considered: delta-theta, alpha, beta bands.</p></sec></sec><sec id="s2-4"><title>Amplitude-envelope correlation</title><p>The AECs are defined as Pearson’s correlation coefficients (PCCs) between any two amplitude envelopes of regional time courses (total <inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>94</mml:mn><mml:mo>×</mml:mo><mml:mn>93</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:mn>4371</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> pairs). Regional time courses were first processed by a band-pass filtering, and then their envelopes were extracted by the Hilbert transform. To discount spurious correlations caused by source leakages, we orthogonalized any two band-limited time courses before computing their envelopes by employing a pairwise orthogonalization (<xref ref-type="bibr" rid="bib21">Hipp et al., 2012</xref>; <xref ref-type="bibr" rid="bib51">Sekihara and Nagarajan, 2015</xref>). The AEC with leakage corrections is often expressed as AEC-c and is known as a robust measure (<xref ref-type="bibr" rid="bib6">Briels et al., 2020b</xref>). The pairwise orthogonalization provides asymmetric values between two-time courses; the value depends on which time course is taken as a seed. Therefore, the PCCs between orthogonalized envelopes for both directions were averaged, resulting in a symmetric AEC matrix. Regional AECs, that represent the connectivity strengths of each ROI, were computed by averaging over row/column components of the symmetric AEC matrix.</p></sec><sec id="s2-5"><title>Spectral power</title><p>The spectral power of a given band, which has often been used as a metric to discriminate patients with AD from controls (<xref ref-type="bibr" rid="bib28">Jeong, 2004</xref>; <xref ref-type="bibr" rid="bib16">Engels et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Wiesman et al., 2021</xref>), is defined by the ratio of a band power to total power and was calculated from regional PSDs. Regional PSDs were calculated from the 94 regional time courses using Welch’s method (50% overlap) with 0.293-Hz <inline-formula><mml:math id="inf8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>/</mml:mo></mml:mrow><mml:mn>2048</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> frequency steps.</p></sec><sec id="s2-6"><title>Scalar neural synchrony metrics</title><p>To identify general trends in changes in long-range and local synchrony with the severity of AD, we performed group comparisons of the regional synchrony metrics between AD patients and controls. Based on the group contrasts of regional metrics observed, we introduced scalar synchrony metrics by calculating the averages within several regions where large region-level group contrasts were identified. The scalar MEG metrics were used in the SAC-EBMs.</p></sec><sec id="s2-7"><title>Metric trajectory analyses</title><sec id="s2-7-1"><title>Event-based sequencing modeling</title><p>Imaging and neuropsychological biomarkers for AD are continuous quantities taking values from normal to severe, while the stages of the disease are discrete and are identified by estimating the values of biomarkers (<xref ref-type="bibr" rid="bib54">Sperling et al., 2011</xref>). As a data-driven disease progression model, an event-based sequencing model (EBM) has been proposed that allows us to make inferences about disease progression from cross-sectional data (<xref ref-type="bibr" rid="bib18">Fonteijn et al., 2012</xref>; <xref ref-type="bibr" rid="bib66">Young et al., 2014</xref>; <xref ref-type="bibr" rid="bib67">Young et al., 2018</xref>). In an EBM, disease progression is described as a series of metric events, where events are defined as the occurrences of abnormal values of metrics, and the values of events act as thresholds to determine discrete stages of disease (<xref ref-type="bibr" rid="bib18">Fonteijn et al., 2012</xref>). The model infers temporal sequences of the events from cross-sectional data.</p><p>It is also possible to set multiple events per metric by defining them as occurrences of taking certain <inline-formula><mml:math id="inf9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores within the range from initial to final <inline-formula><mml:math id="inf10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores (<inline-formula><mml:math id="inf11"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>initial</mml:mi></mml:msub><mml:mo>⁢</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>final</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:math></inline-formula>), in which <inline-formula><mml:math id="inf12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores for each metric linearly increase between all consecutive events and the stages are located at temporal midpoints between the two consecutive event occurrence times (<xref ref-type="bibr" rid="bib67">Young et al., 2018</xref>). In this linear <inline-formula><mml:math id="inf13"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score event model, a metric trajectory is described as a series of metric values evaluated at estimated stages.</p><p>We developed a robust EBM framework to quantify metric trajectories on the basis of the linear <inline-formula><mml:math id="inf14"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score model, employing the following form of a data likelihood:<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munderover><mml:mo>∏</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:munderover><mml:mo>∑</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf15"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>N</mml:mi></mml:mstyle></mml:math></inline-formula> denotes a total number of events, <inline-formula><mml:math id="inf16"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>S</mml:mi></mml:mstyle></mml:math></inline-formula> denotes a sequence of the events, and <inline-formula><mml:math id="inf17"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf18"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf19"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> are the indices of metric, subject, and stage, respectively. <inline-formula><mml:math id="inf20"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>J</mml:mi></mml:mstyle></mml:math></inline-formula> is the number of subjects (<inline-formula><mml:math id="inf21"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mn>148</mml:mn></mml:mstyle></mml:math></inline-formula>). <inline-formula><mml:math id="inf22"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>I</mml:mi></mml:mstyle></mml:math></inline-formula> is the number of metrics: <inline-formula><mml:math id="inf23"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mstyle></mml:math></inline-formula> for an AC-EBM and <inline-formula><mml:math id="inf24"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mstyle></mml:math></inline-formula> for an SAC-EBM, respectively. The symbol <inline-formula><mml:math id="inf25"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>t</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> denotes stages for each subject <inline-formula><mml:math id="inf26"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula>, and a conditional probability, <inline-formula><mml:math id="inf27"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, describes the probability that a subject <inline-formula><mml:math id="inf28"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> takes biomarker values of <inline-formula><mml:math id="inf29"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> given a sequence of events <inline-formula><mml:math id="inf30"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>S</mml:mi></mml:mstyle></mml:math></inline-formula> and that <inline-formula><mml:math id="inf31"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>t</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> (that is, the subject <inline-formula><mml:math id="inf32"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> is in a stage <inline-formula><mml:math id="inf33"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula>). The symbol <inline-formula><mml:math id="inf34"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>I</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mo stretchy="false">]</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">T</mml:mi></mml:mrow></mml:mrow></mml:msup></mml:mstyle></mml:math></inline-formula>, where <inline-formula><mml:math id="inf35"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> denotes the <inline-formula><mml:math id="inf36"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score of a metric <inline-formula><mml:math id="inf37"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula> for a subject <inline-formula><mml:math id="inf38"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula>, and the symbol <inline-formula><mml:math id="inf39"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>Z</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>J</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mstyle></mml:math></inline-formula> describing the data matrix with the <inline-formula><mml:math id="inf40"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>I</mml:mi><mml:mo>×</mml:mo><mml:mi>J</mml:mi></mml:mstyle></mml:math></inline-formula> dimension. Since there are <inline-formula><mml:math id="inf41"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>2</mml:mn></mml:mstyle></mml:math></inline-formula> event occurrence times including initial and final times, <inline-formula><mml:math id="inf42"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:math></inline-formula> stages are provided. When employing <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>, we assumed that the prior distribution in which the subject <inline-formula><mml:math id="inf43"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> is in a stage <inline-formula><mml:math id="inf44"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> is uniform: <inline-formula><mml:math id="inf45"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mstyle></mml:math></inline-formula>. We also assumed that the prior probability of <inline-formula><mml:math id="inf46"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> arises from independent Gaussian distributions for each metric <inline-formula><mml:math id="inf47"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula>, resulting in a multivariate factorized prior. Hence,<disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∝</mml:mo><mml:munderover><mml:mo>∏</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mi>exp</mml:mi><mml:mo>⁡</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mn>2</mml:mn></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula></p><p>The symbol <inline-formula><mml:math id="inf48"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>μ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> denotes a value of the <inline-formula><mml:math id="inf49"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score of a metric <inline-formula><mml:math id="inf50"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula> at a stage <inline-formula><mml:math id="inf51"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> and is given by a linearly interpolated midpoint <inline-formula><mml:math id="inf52"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score between two <inline-formula><mml:math id="inf53"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores evaluated at consecutive event occurrence times. The goal of this formulation is to evaluate the posterior distribution that a subject <inline-formula><mml:math id="inf54"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> belongs to a stage <inline-formula><mml:math id="inf55"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf56"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>S</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, with the most likely order of events <inline-formula><mml:math id="inf57"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>S</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mstyle></mml:math></inline-formula>.</p><p>The most likely order of the events is given by the sequence of events, <inline-formula><mml:math id="inf58"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>S</mml:mi></mml:mstyle></mml:math></inline-formula>, which maximizes the posterior distribution <inline-formula><mml:math id="inf59"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>S</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>Z</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>/</mml:mo></mml:mrow><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Z</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. Under the assumption that the prior <inline-formula><mml:math id="inf60"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> is uniformly distributed (<xref ref-type="bibr" rid="bib18">Fonteijn et al., 2012</xref>), the most likely sequence is obtained by solving the maximum likelihood problem of maximizing <xref ref-type="disp-formula" rid="equ1">Equation 1</xref>. To solve the problem, for a given set of events, we performed Markov chain Monte Carlo (MCMC) sampling on sequences and chose the maximum likelihood sequence from 50,000 MCMC samples. In the generation of the MCMC samples, we initialized the MCMC algorithm with an initial sequence close to or equal to the maximum likelihood solution by running an ascent algorithm 10 times from different initialization points, i.e., randomly generated event sequences (<xref ref-type="bibr" rid="bib18">Fonteijn et al., 2012</xref>).</p></sec><sec id="s2-7-2"><title>z-scoring of metrics</title><p>We computed <inline-formula><mml:math id="inf61"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores of the PHG volume, MMSE score, and scalar neural synchrony metrics to utilize them in the EBM frameworks. Since a linear <inline-formula><mml:math id="inf62"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score model assumes a monotonous increase in <inline-formula><mml:math id="inf63"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scored metrics along disease progression (i.e. higher stage denotes more severity), ‘sign-inverted’ <inline-formula><mml:math id="inf64"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores were introduced to the metrics with decreasing trends along disease progression. Specifically, for GM volumes, MMSE score, and neural synchrony metrics in the alpha and beta bands, the <inline-formula><mml:math id="inf65"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score of a metric <inline-formula><mml:math id="inf66"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula> for a subject <inline-formula><mml:math id="inf67"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> was defined by <inline-formula><mml:math id="inf68"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>/</mml:mo></mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msubsup></mml:mstyle></mml:math></inline-formula>, where <inline-formula><mml:math id="inf69"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> denotes a value of a metric <inline-formula><mml:math id="inf70"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula> for a subject <inline-formula><mml:math id="inf71"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf72"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msubsup></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf73"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msubsup></mml:mstyle></mml:math></inline-formula> denote the mean and standard deviation (SD) of the metric values of the controls, respectively. For the delta-theta-band neural synchrony metrics, <inline-formula><mml:math id="inf74"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores were defined in a standard way as <inline-formula><mml:math id="inf75"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>/</mml:mo></mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">C</mml:mi></mml:mrow></mml:mrow></mml:msubsup></mml:mstyle></mml:math></inline-formula>. Using these <inline-formula><mml:math id="inf76"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scored metrics, the initial and final events, <inline-formula><mml:math id="inf77"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf78"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, for each metric were set as the bottom and top 10% average <inline-formula><mml:math id="inf79"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, respectively.</p></sec><sec id="s2-7-3"><title>Events-setting optimization</title><p>In addition to the initial and final events of the <inline-formula><mml:math id="inf80"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score, <inline-formula><mml:math id="inf81"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and <inline-formula><mml:math id="inf82"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, we set three events for each metric because various possible curves of the metric trajectories were supposed to be well expressed by three variable points with two fixed points. For example, in an AC-EBM analysis, that is, a two-metric trajectory analysis for PHG volume loss and MMSE decline, a total of six events were considered <inline-formula><mml:math id="inf83"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>6</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. The metric trajectory as a series of stage values <inline-formula><mml:math id="inf84"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>μ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> is sensitive to event settings because predefined events do not necessarily capture appropriate boundaries between disease stages. To determine disease stages less sensitive to specifications of the <inline-formula><mml:math id="inf85"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events, we tried several sets of events and selected the set of events with the highest data likelihood among the trials. Specifically, we searched for the set of events that better fits the data <inline-formula><mml:math id="inf86"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>Z</mml:mi></mml:mstyle></mml:math></inline-formula> by trying all combinations of three <inline-formula><mml:math id="inf87"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores from <inline-formula><mml:math id="inf88"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo fence="false" stretchy="false">{</mml:mo><mml:mn>0.2</mml:mn><mml:mo>,</mml:mo><mml:mn>0.3</mml:mn><mml:mo>,</mml:mo><mml:mn>0.4</mml:mn><mml:mo>,</mml:mo><mml:mn>0.5</mml:mn><mml:mo>,</mml:mo><mml:mn>0.6</mml:mn><mml:mo>,</mml:mo><mml:mn>0.7</mml:mn><mml:mo>,</mml:mo><mml:mn>0.8</mml:mn><mml:mo fence="false" stretchy="false">}</mml:mo></mml:mstyle></mml:math></inline-formula>-quantiles for each metric. The number of combinations of events for each metric was accordingly <inline-formula><mml:math id="inf89"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mn>35</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. Therefore, MCMC samplings (50,000 samples for each set of events) were performed 1225 times for an AC-EBM and 42,875 times for an SAC-EBM, respectively, to find the set of events and their sequence <inline-formula><mml:math id="inf90"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>S</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mstyle></mml:math></inline-formula> with the highest data likelihood. This exhaustive search for optimal event settings, which was not implemented in a conventional linear z-score EBM (<xref ref-type="bibr" rid="bib67">Young et al., 2018</xref>), is shown schematically in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</p><p>Although it is tractable to directly evaluate <inline-formula><mml:math id="inf91"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>Z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mi>S</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> for all ordered arrangements of <inline-formula><mml:math id="inf92"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events when the number of the permutations for each set of <inline-formula><mml:math id="inf93"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events is just <inline-formula><mml:math id="inf94"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>20</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> for <inline-formula><mml:math id="inf95"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mstyle></mml:math></inline-formula> (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) and <inline-formula><mml:math id="inf96"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>1680</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mn>9</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mo>×</mml:mo><mml:mrow><mml:mn>6</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> for <inline-formula><mml:math id="inf97"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mn>3</mml:mn></mml:mstyle></mml:math></inline-formula>, such a direct evaluation is not tractable when <inline-formula><mml:math id="inf98"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>I</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> and requires MCMC sampling. Furthermore, MCMC enables the computation of sequence statistics. Therefore, we used MCMC sampling from which we could compute the positional variance estimates for each event (see <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>).</p></sec></sec><sec id="s2-8"><title>Trajectory computations</title><p>Given the most likely sequence <inline-formula><mml:math id="inf99"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>S</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow></mml:mstyle></mml:math></inline-formula> as a result of the exhaustive search, the probabilities that a subject <inline-formula><mml:math id="inf100"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> falls into a stage <inline-formula><mml:math id="inf101"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> are evaluated by the posterior distribution:<disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≡</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:msub><mml:mi>Z</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>S</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>S</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:munder><mml:mo>∑</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munder><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Z</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>S</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:math></disp-formula></p><p>These probabilities describe the contribution of a subject <inline-formula><mml:math id="inf102"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> to stage <inline-formula><mml:math id="inf103"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula>, allowing us to evaluate the stage value of any metric <inline-formula><mml:math id="inf104"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>x</mml:mi></mml:mstyle></mml:math></inline-formula> of <inline-formula><mml:math id="inf105"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula> at a stage <inline-formula><mml:math id="inf106"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> as a weighted mean:<disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>⋅</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:math></disp-formula></p><p>Then, we represented the trajectory of the metric <inline-formula><mml:math id="inf107"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula> by a series of the stage values, <inline-formula><mml:math id="inf108"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. The standard error (SE) of the weighted mean at stage <inline-formula><mml:math id="inf109"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> was evaluated by<disp-formula id="equ5"><label>(5)</label><mml:math id="m5"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>σ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>⋅</mml:mo><mml:msqrt><mml:mfrac><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mfrac></mml:msqrt><mml:mo>,</mml:mo></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf110"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>σ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> is a standard deviation of a metric <inline-formula><mml:math id="inf111"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula>. This definition of SE provides an usual expression of the standard error of the mean, <inline-formula><mml:math id="inf112"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>σ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>/</mml:mo></mml:mrow><mml:msqrt><mml:mi>J</mml:mi></mml:msqrt></mml:mstyle></mml:math></inline-formula>, if all subjects contributed equally to all stages.</p><p>These formulations of trajectories were applied to several metrics. In the AC-EBM, the metrics <inline-formula><mml:math id="inf113"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula> denote the PHG volume loss <inline-formula><mml:math id="inf114"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score and the MMSE scores. In the SAC-EBM, they denote each scalar neural synchrony metric in addition to the PHG volume loss <inline-formula><mml:math id="inf115"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score and the MMSE score. We also used <xref ref-type="disp-formula" rid="equ4">Equation 4</xref> to evaluate the progressions of the regional neural synchrony metrics and the regional GM volume loss <inline-formula><mml:math id="inf116"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores along the estimated EBM stages. When evaluating the proportion of subjects classified into each stage, we treated <inline-formula><mml:math id="inf117"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>J</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> as a vector in which a metric <inline-formula><mml:math id="inf118"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula> represents a category of subjects provided by the CDR scale. For example, when evaluating the ratio of subject with CDR <inline-formula><mml:math id="inf119"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>0.5</mml:mn></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf120"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:math></inline-formula> only when a subject <inline-formula><mml:math id="inf121"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> has CDR scale of 0.5, otherwise <inline-formula><mml:math id="inf122"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mstyle></mml:math></inline-formula>.</p></sec><sec id="s2-9"><title>Statistical analyses</title><p>To test demographic differences between AD patients and controls, the unpaired <inline-formula><mml:math id="inf123"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>t</mml:mi></mml:mstyle></mml:math></inline-formula>-test was used for age and the chi-square test for sex. The age was defined at the time of the MEG scan date. In statistical analyses, p-values below 0.05 were considered statistically significant. For group comparisons of GM volumes, MMSE scores, and neural synchrony metrics, two-sided significance tests (against a null value of zero) were performed using the general linear model (GLM). For statistical tests on GM volumes, TIV, age, and the difference between MRI and MEG dates were included as covariates. For statistical tests on MMSE scores, age and the difference between MMSE and MEG dates were included as covariates. For statistical tests of neural synchrony metrics, age was included as a covariate. The problem of multiple comparisons between 94 regions was solved by controlling the Benjamini-Hochberg false discovery rate (FDR) (<xref ref-type="bibr" rid="bib4">Benjamini and Hochberg, 1995</xref>). The FDR-adjusted <inline-formula><mml:math id="inf124"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi></mml:mstyle></mml:math></inline-formula>-value (i.e., <inline-formula><mml:math id="inf125"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>q</mml:mi></mml:mstyle></mml:math></inline-formula>-value) below 0.05 or 001 was considered statistically significant.</p><p>A non-parametric test was performed to statistically compare metrics between stages, i.e., to test statistical significance of the difference between stage values represented by weighted means [e.g. stage <inline-formula><mml:math id="inf126"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> vs <inline-formula><mml:math id="inf127"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msup><mml:mo>:</mml:mo><mml:mi>δ</mml:mi><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>k</mml:mi><mml:mrow><mml:mi mathvariant="normal">′</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>]. For a metric <inline-formula><mml:math id="inf128"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>i</mml:mi></mml:mstyle></mml:math></inline-formula>, we used bootstrap resampling (50,000 samples) of an original data set, <inline-formula><mml:math id="inf129"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">𝒙</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>⁢</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>⁢</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi mathvariant="normal">…</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>⁢</mml:mo><mml:mi>J</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>, to generate new data sets, <inline-formula><mml:math id="inf130"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>J</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, using a random number generator, where each <inline-formula><mml:math id="inf131"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msubsup></mml:mstyle></mml:math></inline-formula> is one of the components of the original data set <inline-formula><mml:math id="inf132"><mml:msub><mml:mi mathvariant="bold-italic">𝒙</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula>. We then calculated the weighted means <inline-formula><mml:math id="inf133"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> (<xref ref-type="disp-formula" rid="equ4">Equation 4</xref>) for each sample. The same procedures were performed for stage <inline-formula><mml:math id="inf134"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msup><mml:mi>k</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi class="MJX-variant" mathvariant="normal">′</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:math></inline-formula>, obtaining weighted means <inline-formula><mml:math id="inf135"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msubsup><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>k</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi class="MJX-variant" mathvariant="normal">′</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> for each sample. We then tested the null hypothesis that a weighted mean in stage <inline-formula><mml:math id="inf136"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf137"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, is equal to a weighted mean in stage <inline-formula><mml:math id="inf138"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msup><mml:mi>k</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi class="MJX-variant" mathvariant="normal">′</mml:mi></mml:mrow></mml:msup></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf139"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>k</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi class="MJX-variant" mathvariant="normal">′</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, evaluating the null distribution of differences in the weighted mean values, <inline-formula><mml:math id="inf140"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>δ</mml:mi><mml:msup><mml:mi>x</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msubsup><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msubsup><mml:mrow class="MJX-TeXAtom-ORD"><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">¯</mml:mo></mml:mover></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mo>⋆</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>k</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi class="MJX-variant" mathvariant="normal">′</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. The problem of multiple comparisons across stages was solved by controlling the FDR. The <inline-formula><mml:math id="inf141"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>q</mml:mi></mml:mstyle></mml:math></inline-formula>-value below 005 was considered statistically significant.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Participant demographics</title><p>This study included a cohort of 78 patients with AD (50 female; 28 male) including 35 patients with AD dementia and 43 patients with MCI due to AD, and also included 70 cognitively-unimpaired older adults as controls (41 female; 29 male). The CDR scales were 0 for the cognitively-unimpaired controls, 0.5 for patients with MCI, and <inline-formula><mml:math id="inf142"><mml:mrow><mml:mn>1</mml:mn><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>27</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> or <inline-formula><mml:math id="inf143"><mml:mrow><mml:mn>2</mml:mn><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>8</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> for patients with AD dementia. There were no differences in sex distribution between the AD and control groups [<inline-formula><mml:math id="inf144"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msup><mml:mi>χ</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0.477</mml:mn><mml:mo>;</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.49</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>]. The average age at the time of MEG was slightly higher in the control group than patients with AD (controls, mean ± SE: <inline-formula><mml:math id="inf145"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>70.5</mml:mn><mml:mo>±</mml:mo><mml:mn>0.99</mml:mn></mml:mstyle></mml:math></inline-formula>, range: 49.5–87.7; AD, mean ± SE: <inline-formula><mml:math id="inf146"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>63.9</mml:mn><mml:mo>±</mml:mo><mml:mn>1.01</mml:mn></mml:mstyle></mml:math></inline-formula>, range: 49.0–84.4) [unpaired <inline-formula><mml:math id="inf147"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>t</mml:mi></mml:mstyle></mml:math></inline-formula>-test: <inline-formula><mml:math id="inf148"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>t</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>146</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>4.708</mml:mn><mml:mo>;</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>p</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.001</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>]. The mean MMSE in patients with AD was <inline-formula><mml:math id="inf149"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>22.7</mml:mn><mml:mo>±</mml:mo><mml:mn>0.43</mml:mn></mml:mstyle></mml:math></inline-formula> (mean ± SE) while the mean MMSE in the controls <inline-formula><mml:math id="inf150"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>29.2</mml:mn><mml:mo>±</mml:mo><mml:mn>0.48</mml:mn></mml:mstyle></mml:math></inline-formula>. MMSE scores were adjusted for age and time differences between MMSE administration and MEG scan using a GLM (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3B</xref>). MMSE-decline <inline-formula><mml:math id="inf151"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, <inline-formula><mml:math id="inf152"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, were standardized by adjusted MMSE scores of the control group and sign-inverted (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Atrophy-cognition event-based sequencing model (EBM) staging of Alzheimer’s disease (AD) progression.</title><p>(<bold>A</bold>) Histogram of parahippocampal gyrus (PHG) volume loss <inline-formula><mml:math id="inf153"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, <inline-formula><mml:math id="inf154"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. (<bold>B</bold>) Histogram of mini-mental state examination (MMSE)-decline <inline-formula><mml:math id="inf155"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, <inline-formula><mml:math id="inf156"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>. The <inline-formula><mml:math id="inf157"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores for PHG volume loss and MMSE were standardized by the adjusted scores of the control group and sign-inverted so that higher <inline-formula><mml:math id="inf158"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores denote more severity. (<bold>C</bold>) Posterior probabilities, <inline-formula><mml:math id="inf159"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, that a subject <inline-formula><mml:math id="inf160"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> belongs to a stage <inline-formula><mml:math id="inf161"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> evaluated by the Atrophy-Cognition EBM (AC-EBM). (<bold>D</bold>) The ratio of subjects classified to each stage; blue: Control (clinical dementia rating, CDR 0), orange: MCI due to AD (CDR 0.5), pink: mild AD dementia (CDR 1), and red: moderate AD dementia (CDR 2). (<bold>E</bold>) Distribution of the stages in the space spanned by PHG volume loss and MMSE score. Each subject <inline-formula><mml:math id="inf162"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> was distinctly assigned to one of the stages with the highest posterior probability, <inline-formula><mml:math id="inf163"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>p</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. The colors of the dots denote the seven stages. A star symbol denotes the probability-based weighted means of <inline-formula><mml:math id="inf164"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> and MMSE scores at stage 4 and MMSE <inline-formula><mml:math id="inf165"><mml:mrow><mml:mi/><mml:mo>=</mml:mo><mml:mrow><mml:mn>26.3</mml:mn><mml:mo>⁢</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mo>±</mml:mo><mml:mn>0.82</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula>. The values in parentheses denote the standard error (SE; <xref ref-type="disp-formula" rid="equ5">Equation 5</xref>) of the weighted means. (<bold>F</bold>) Trajectories of PHG volume loss and MMSE score as a function of the seven stages. Probability-based weighted means (± SE) are shown. The initial and final <inline-formula><mml:math id="inf166"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores used in the AC-EBM were: <inline-formula><mml:math id="inf167"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>1.372</mml:mn><mml:mo>,</mml:mo><mml:mn>3.804</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> for PHG volume loss and <inline-formula><mml:math id="inf168"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>0.902</mml:mn><mml:mo>,</mml:mo><mml:mn>12.712</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> for MMSE decline, respectively. (<bold>G</bold>) Progression of GM volume loss (<inline-formula><mml:math id="inf169"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores) from stage 1–7. Regional gray matter (GM) atrophy in the predicted stage of mild cognitive impairment (MCI) (stage 4) was circled with a dotted line.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Steps for computing metric trajectories.</title><p>The metrics-trajectory computation steps in the Atrophy-Cognition EBM (AC-EBM) are illustrated. Similar steps were executed for the SAC-EBMs. In an SAC-EBM, the number of iterations in Step 1 was <inline-formula><mml:math id="inf170"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mo>×</mml:mo><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mo>×</mml:mo><mml:mrow><mml:mn>7</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mn>42</mml:mn><mml:mo>,</mml:mo><mml:mn>875</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>. A diagram shown at the bottom of Step 1 represents the relationship between the events and stages in a linear <inline-formula><mml:math id="inf171"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score model. A stage is located between two consecutive event occurrence times and its model value (<inline-formula><mml:math id="inf172"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>μ</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>) is given by a midpoint value. When a total of <inline-formula><mml:math id="inf173"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>N</mml:mi></mml:mstyle></mml:math></inline-formula> events is set, the models provide <inline-formula><mml:math id="inf174"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>N</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mstyle></mml:math></inline-formula> event-based sequencing model (EBM) stages. Positional variance diagrams of the <inline-formula><mml:math id="inf175"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events created from the 50,000 Markov chain Monte Carlo (MCMC) samples indicated that there was no uncertainty in the predicted positions of selected <inline-formula><mml:math id="inf176"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events. Another example of positional variance with positional uncertainty has been shown in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>An example of positional variance diagram of <inline-formula><mml:math id="inf177"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events.</title><p>The <inline-formula><mml:math id="inf178"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events, <inline-formula><mml:math id="inf179"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>PHG</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mi>E1</mml:mi><mml:mo>⁢</mml:mo><mml:mi>E2</mml:mi><mml:mo>⁢</mml:mo><mml:mi>E3</mml:mi></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>0.5 0.75 1.5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and,<inline-formula><mml:math id="inf180"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mi>MMSE</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mi>E4</mml:mi><mml:mo>⁢</mml:mo><mml:mi>E5</mml:mi><mml:mo>⁢</mml:mo><mml:mi>E6</mml:mi></mml:mrow><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>0.1 0.3 3.0</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> were selected. Markov chain Monte Carlo (MCMC) sampling (50,000 samples) was performed to find an optimal sequence of events. It should be noted that this set of <inline-formula><mml:math id="inf181"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events was not used in the Atrophy-Cognition EBM (AC-EBM) shown in the main text. This figure is intended to show just an example of positional variance diagrams with positional uncertainty. In the AC-EBM shown in the main text, we obtained the positional variance diagrams without positional uncertainty for the optimal sets of <inline-formula><mml:math id="inf182"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Group comparisons of parahippocampal gyrus (PHG) volumes and mini-mental state examination (MMSE) scores.</title><p>(<bold>A</bold>) Group comparison of PHG volume [unpaired <inline-formula><mml:math id="inf183"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>t</mml:mi></mml:mstyle></mml:math></inline-formula>-test: t(143) = -9.508; ***<italic>p</italic> &lt; 0.001] based on <inline-formula><mml:math id="inf184"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>T</mml:mi></mml:mstyle></mml:math></inline-formula>-statistic while adjusting for the effects of total intracranial volume (TIV), age, and the difference between MRI and magnetoencephalography (MEG) dates. The PHG volume was defined as the sum of the volumes of PHGs from the left and right hemispheres. The average PHG volume in patients with Alzheimer’s disease (AD) was <inline-formula><mml:math id="inf185"><mml:mrow><mml:mrow><mml:mn>7.99</mml:mn><mml:mo>⁢</mml:mo><mml:mi>ml</mml:mi></mml:mrow><mml:mo>±</mml:mo><mml:mn>0.09</mml:mn></mml:mrow></mml:math></inline-formula>, and the average PHG volume in controls <inline-formula><mml:math id="inf186"><mml:mrow><mml:mrow><mml:mn>9.28</mml:mn><mml:mo>⁢</mml:mo><mml:mi>ml</mml:mi></mml:mrow><mml:mo>±</mml:mo><mml:mn>0.11</mml:mn></mml:mrow></mml:math></inline-formula>. (<bold>B</bold>) Group comparison of mini-mental state examination (MMSE) scores [unpaired <inline-formula><mml:math id="inf187"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>t</mml:mi></mml:mstyle></mml:math></inline-formula>-test: t(144) = -10.171; ***<italic>p</italic> &lt; 0.001] based on <inline-formula><mml:math id="inf188"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>T</mml:mi></mml:mstyle></mml:math></inline-formula>-statistic while adjusting for the effects of age and the difference between MMSE and MEG dates. MMSEs were performed within an average of 0.48 years (range: -2.83–1.50) and 0.22 years (range: -1.52–1.01) of the evaluation of MEG for controls and patients, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Group comparison of gray matter (GM) volumes.</title><p>Group comparisons of GM volume for each of the 94 anatomical regions included in the Automated Anatomical Labeling 3 (AAL3) atlas were performed by computing <inline-formula><mml:math id="inf189"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>T</mml:mi></mml:mstyle></mml:math></inline-formula>- and <inline-formula><mml:math id="inf190"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>p</mml:mi></mml:mstyle></mml:math></inline-formula>-values using general linear models (GLMs) with total intracranial volume (TIV), age, and the difference between MRI and magnetoencephalography (MEG) dates as covariates. Eighty-seven regional GM volumes were significantly smaller in patients with Alzheimer’s disease (AD) than in controls, especially in the temporal regions. <inline-formula><mml:math id="inf191"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>T</mml:mi></mml:mstyle></mml:math></inline-formula>-values exceeding threshold (<inline-formula><mml:math id="inf192"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>q</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, false discovery rate (FDR) corrected) were displayed. Top 10 regions with significant group differences are listed in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig1-figsupp4-v2.tif"/></fig></fig-group><p>Group comparisons of GM volumes for each of the anatomical regions included in the AAL3 atlas showed that GM volumes in the temporal regions are significantly smaller in AD patients than in controls (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>; <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4</xref>). Among temporal GM volumes, we focused on a volume of PHG as a key indicator of neurodegeneration in AD progression. The PHG includes the perirhinal and entorhinal cortices of the medial temporal lobe (MTL), and MRI-based studies have reported that MTL volume decreases, especially in the perirhinal and entorhinal cortices, in the early stages of typical AD (<xref ref-type="bibr" rid="bib58">Teipel et al., 2006</xref>; <xref ref-type="bibr" rid="bib15">Echávarri et al., 2011</xref>; <xref ref-type="bibr" rid="bib31">Matsuda, 2016</xref>). In this study, PHG volume was defined as a sum of the volumes of left- and right-hemisphere PHGs. The average volume of PHG in AD patients (<inline-formula><mml:math id="inf193"><mml:mrow><mml:mrow><mml:mn>7.99</mml:mn><mml:mo>⁢</mml:mo><mml:mi>ml</mml:mi></mml:mrow><mml:mo>±</mml:mo><mml:mn>0.09</mml:mn></mml:mrow></mml:math></inline-formula>) was significantly lower than in controls (<inline-formula><mml:math id="inf194"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>9.28</mml:mn><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow><mml:mo>±</mml:mo><mml:mn>0.11</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>) [unpaired <inline-formula><mml:math id="inf195"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>t</mml:mi></mml:mstyle></mml:math></inline-formula>-test: t(143) = -9.508; ***<italic>p</italic> &lt; 0.001] (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A</xref>); the PHG volumes were adjusted for TIV, age, and the difference between MRI and MEG dates by including them in a GLM as covariates. PHG volume loss <inline-formula><mml:math id="inf196"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, <inline-formula><mml:math id="inf197"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, were standardized by the adjusted PHG volumes of the control group and sign-inverted (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p></sec><sec id="s3-2"><title>Abnormal frequency-specific long-range and local neural synchrony in AD</title><p>We performed group comparisons of MEG metrics. Three canonical frequency bands were considered: <inline-formula><mml:math id="inf198"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>2</mml:mn><mml:mo>−</mml:mo><mml:mn>7</mml:mn><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">z</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> (delta-theta), <inline-formula><mml:math id="inf199"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>8</mml:mn><mml:mo>−</mml:mo><mml:mn>12</mml:mn><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">z</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> (alpha), and <inline-formula><mml:math id="inf200"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mn>15</mml:mn><mml:mo>−</mml:mo><mml:mn>29</mml:mn><mml:mspace width="thinmathspace"/><mml:mrow><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">z</mml:mi></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> (beta) bands (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). For regional long-range synchrony (AEC), increases in delta-theta-band synchrony in patients with AD were identified in frontal regions, and reductions in alpha- and beta-band synchrony were identified in the whole brain (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C, E</xref>; <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). These regional contrasts were similar to those observed between AD dementia and subjective cognitive decline (SCD) in MEG/EEG studies (<xref ref-type="bibr" rid="bib48">Schoonhoven et al., 2022</xref>; <xref ref-type="bibr" rid="bib5">Briels et al., 2020a</xref>). For regional local synchrony (spectral power), increases in delta-theta-band power in patients with AD were identified in the whole brain, and reductions in alpha- and beta-band power were identified in temporal regions and the whole brain, respectively (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D, F</xref>; <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). These regional contrasts were similar to those observed between MCI and controls in a multicenter study of MEG (<xref ref-type="bibr" rid="bib23">Hughes et al., 2019</xref>).</p><p>Based on the group contrasts of regional metrics observed, we introduced six scalar metrics to quantify long-range and local synchrony: [i] frontal delta-theta-band AEC, [ii] whole-brain alpha-band AEC, [iii] whole-brain beta-band AEC, [iv] whole-brain delta-theta-band spectral power, [v] temporal alpha-band spectral power, and [vi] whole-brain beta-band spectral power. We computed the average within several regions where large group contrasts were identified at the region level (the temporal and frontal regions of interest (ROI) are illustrated in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Consistent with regional group comparisons, the long-range and local synchrony scalar metrics in delta-theta band increased in AD patients compared to controls, and the long-range and local synchrony scalar metrics in alpha and beta bands were reduced in AD patients compared to controls (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A, B</xref>). We also calculated the <inline-formula><mml:math id="inf201"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, <inline-formula><mml:math id="inf202"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, of each scalar metric that was used in the SAC-EBMs.</p></sec><sec id="s3-3"><title>PHG volume loss precedes the MMSE decline in AD progression</title><p>An AC-EBM analysis with the two metrics, PHG volume loss, <inline-formula><mml:math id="inf203"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and MMSE decline, <inline-formula><mml:math id="inf204"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, was performed for six events (<inline-formula><mml:math id="inf205"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>6</mml:mn></mml:mstyle></mml:math></inline-formula>; three events for each metric). Robust event thresholds were determined by the exhaustive search of multiple event thresholds (<inline-formula><mml:math id="inf206"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score thresholds) and choosing the set of event thresholds that maximize the data likelihood (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>). The AC-EBM provided seven stages, each located between consecutive event occurrence times. The resulting posterior probabilities, <inline-formula><mml:math id="inf207"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, that a subject <inline-formula><mml:math id="inf208"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> belongs to a stage <inline-formula><mml:math id="inf209"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> are shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>. Based on the probabilities, the ratio of subjects classified into each stage was calculated as the probability-based weighted mean (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The ratio of subjects with CDR 05 was highest in stage 4, and the ratio of controls with CDR 0 in stage 4 was small compared to those in less severe stages of 1–3, indicating that stage 4 corresponds best to clinical MCI due to AD.</p><p>The trajectory of PHG volume loss preceded that of MMSE decline (<xref ref-type="fig" rid="fig1">Figure 1F</xref>), consistent with the relationship between brain atrophy and cognitive decline described in a hypothetical model of biomarker trajectories (<xref ref-type="bibr" rid="bib24">Jack et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Sperling et al., 2011</xref>). <xref ref-type="fig" rid="fig1">Figure 1E</xref> visualizes the distribution of the seven stages in the PHG volume loss versus MMSE score. At stage 4, the value of <inline-formula><mml:math id="inf210"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> of <inline-formula><mml:math id="inf211"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>1.33</mml:mn><mml:mo>±</mml:mo><mml:mn>0.258</mml:mn></mml:mstyle></mml:math></inline-formula> was in the range of 1–2. This <inline-formula><mml:math id="inf212"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score range of PHG volume loss corresponds to a mild-atrophy range representing approximately the MCI stage, e.g., in the voxel-based specific regional analysis system for AD (VSRAD) software (<xref ref-type="bibr" rid="bib22">Hirata et al., 2005</xref>; <xref ref-type="bibr" rid="bib30">Matsuda et al., 2012</xref>). Furthermore, the MMSE score of <inline-formula><mml:math id="inf213"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mn>26.3</mml:mn><mml:mo>±</mml:mo><mml:mn>0.82</mml:mn></mml:mstyle></mml:math></inline-formula> at stage 4 was in the range of 23–27. This range of MMSE scores is considered typical for MCI due to AD (<xref ref-type="bibr" rid="bib61">Tsoi et al., 2015</xref>). Stage 4, therefore, corresponds to MCI stage, whereas stages 3 and 5 correspond to preclinical-AD and mild AD-dementia stages, respectively.</p><p>The GM volume <inline-formula><mml:math id="inf214"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores as a function of the seven stages showed that prominent atrophy with <inline-formula><mml:math id="inf215"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>z</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> is observed in the temporal regions starting at stage 4 (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). This trajectory of GM volume approximated the evolution of brain atrophy in the typical progression of AD reported in MRI-based studies; GM volume loss in AD starts in the MTL in the MCI stage, spreads to the lateral temporal and parietal lobes in the mild AD-dementia stage, and spreads further to the frontal lobe in moderate AD-dementia (<xref ref-type="bibr" rid="bib47">Scahill et al., 2002</xref>; <xref ref-type="bibr" rid="bib60">Tondelli et al., 2012</xref>; <xref ref-type="bibr" rid="bib25">Jack et al., 2013</xref>).</p><p>These results of the AC-EBM indicate that the PHG volume loss precedes the MMSE decline, and their metric changes track the stages of AD from preclinical AD to moderate AD-dementia. The order of events for GM volume loss and cognitive decline was consistent with the observation that cognitive decline in the early stage of AD progression reflects neuronal loss in the medial temporal regions (<xref ref-type="bibr" rid="bib26">Jack et al., 2018</xref>; <xref ref-type="bibr" rid="bib13">DeTure and Dickson, 2019</xref>).</p></sec><sec id="s3-4"><title>Neural synchrony progressively changes throughout the AD stages estimated by AC-EBM</title><p>For the seven stages determined by the AC-EBM (<xref ref-type="fig" rid="fig1">Figure 1E–G</xref>), long-range and local neural synchrony profiles were estimated (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Along the EBM stages, the delta-theta-band synchrony was consistently increased and the alpha and beta-band synchrony was consistently decreased. Neural synchrony showed prominent changes around stage 4 (clinical stage of MCI due to AD). The long-range synchrony in the alpha and beta bands decreased steadily in stages 1–3 and then decreased further in stage 4 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Local synchrony in the beta band also decreased by half from 1 to 4 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). On the contrary, there were little changes in delta-theta-band long-range synchrony and delta-theta- and alpha-band local synchrony from stage 1 to 3 but these changes became prominent after stage 3.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Profiles of neural synchrony as a function of the Alzheimer’s disease (AD) stages estimated by Atrophy-Cognition EBM (AC-EBM).</title><p>(<bold>A,B</bold>) Profiles of amplitude-envelope correlation (AEC) (<bold>A</bold>) and spectral power (<bold>B</bold>) as a function of the seven stages, showing probability-based weighted means (± SE). Neural synchrony increased monotonously with AD progression in the delta-theta band and decreased monotonously in the alpha and beta bands. (<bold>C,D</bold>) Regional AEC (<bold>C</bold>) and spectral power (<bold>D</bold>) as a function of the seven stages. Deviations from the neural-synchrony spatial patterns averaged over the controls are displayed. The deviations were evaluated using the probability-based weighted means of <inline-formula><mml:math id="inf216"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores standardized by the controls. Spatial patterns in the mild cognitive impairment (MCI) stage (stage 4) were circled with dotted lines. (<bold>E,F</bold>) Changes in neural synchrony during the preclinical stages. Regional comparisons between two stages (stages 4 vs 1) are shown based on non-parametric tests of weighted mean differences <inline-formula><mml:math id="inf217"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>δ</mml:mi><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>. Differences that exceed the threshold (<inline-formula><mml:math id="inf218"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>q</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>) are displayed. There were no significant differences in long-range synchrony in the delta-theta band.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Normalized power spectral densities (PSDs) for the Alzheimer’s disease (AD) and control groups.</title><p>Power spectral densities (PSDs) were averaged in all regions of the brain (94 Automated Anatomical Labeling 3, AAL3 atlas) for controls and AD patients, respectively. Their 95% confidence intervals are also shown. The shaded areas in the frequency axis denote the canonical frequency bands: delta-theta (2–7 Hz), alpha (8–12 Hz), and beta (15–29 Hz) bands. In terms of the average PSD in AD, a clear alpha peak disappeared. Alpha frequencies in each region in AD patients generally decrease (i.e. alpha slowing) compared to controls. The magnitude of alpha slowing depends on brain regions as well as AD severity; for example, alpha slowing is prominent in temporal regions. Averaging over PSD curves with different alpha peaks results in the disappearance of an alpha peak in the average PSD in patients with AD.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Group comparisons of magnetoencephalography (MEG) metrics.</title><p>(<bold>A,B</bold>) Group comparisons (violin plots) and <inline-formula><mml:math id="inf219"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score histograms of the six scalar MEG metrics: [i] frontal delta-theta-band amplitude-envelope correlation (AEC), [ii] whole-brain alpha-band AEC, [iii] whole-brain beta-band AEC, [iv] whole-brain delta-theta-band spectral power, [v] temporal alpha-band spectral power, and [vi] whole-brain beta-band spectral power. Group comparisons were performed by <inline-formula><mml:math id="inf220"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>T</mml:mi></mml:mstyle></mml:math></inline-formula>-statistics while adjusting for the effect of age (***p &lt; 0.001). In terms of the <inline-formula><mml:math id="inf221"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores of the scalar MEG metrics, raw <inline-formula><mml:math id="inf222"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score values in alpha and beta bands were negative in patients with AD, and therefore we defined, <inline-formula><mml:math id="inf223"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula> multiplying the values by -1 so that higher <inline-formula><mml:math id="inf224"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores denote more severity. The sign-inverted <inline-formula><mml:math id="inf225"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores were included in the SAC-EBMs. (C–F) Group comparisons of the regional MEG metrics based on <inline-formula><mml:math id="inf226"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>T</mml:mi></mml:mstyle></mml:math></inline-formula>-statistic maps of region-wise comparisons (94 Automated Anatomical Labeling 3 , AAL3-atlas regions) while adjusting for the effect of age. For the regional AECs, we considered the connectivity strengths of each ROI. The unit of spectral power is a percentage of total power. <inline-formula><mml:math id="inf227"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>T</mml:mi></mml:mstyle></mml:math></inline-formula>-values exceeding thresholds (<inline-formula><mml:math id="inf228"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>q</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> for long-range synchrony (<bold>E</bold>) and <inline-formula><mml:math id="inf229"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>q</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.01</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula> for local synchrony (<bold>F</bold>), false discovery rate,FDR corrected) are displayed. The top 10 regions with significant group differences in long-range (<bold>E</bold>) and local (<bold>F</bold>) synchrony are listed in <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref> and <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Frontal and temporal regions of interest.</title><p>The regions of interests (ROIs) were based on group differences in neural synchrony metrics between patients with Alzheimer’s disease (AD) and controls. ROIs were selected symmetrically for the left and right hemispheres from the regions where large group contrasts were identified (see <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3E</xref>). (<bold>F</bold>). For the frontal delta-theta-band amplitude-envelope correlation (AEC), 12 subregions were chosen mainly from the frontal area: left and right precentral, superior frontal (dorsolateral/medial), middle frontal, anterior cingulate and paracingulate gyri, and supplementary motor areas. For the temporal alpha-band spectral power, 20 subregions were chosen from the temporal area: left and right parahippocampal, lingual, superior/middle/inferior occipital, fusiform, superior/middle/inferior temporal gyri, and precunei.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig2-figsupp3-v2.tif"/></fig></fig-group><p>Regional patterns of long-range and local synchrony as a function of the seven stages indicated that prominent changes manifest themselves at stage 4 (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>; <xref ref-type="supplementary-material" rid="supp7">Supplementary file 7</xref> and <xref ref-type="supplementary-material" rid="supp8">Supplementary file 8</xref>). The regions with prominent deviations overlapped with the regions where a significant increase and decrease in neural synchrony was observed in the group comparisons (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E, F</xref>).</p><p>The changes in neural synchrony metrics with AD progression indicate that neural synchrony is a sensitive indicator of functional change along AD progression. To further investigate the temporal association of functional deficits with neurodegeneration and cognitive decline, we included neural synchrony in addition to the PHG volume loss and MMSE decline in the EBM frameworks, performing SAC-EBMs.</p></sec><sec id="s3-5"><title>Long-range synchrony changes in the alpha and beta bands precede PHG volume loss and MMSE decline</title><p>SAC-EBMs that include PHG volume loss, <inline-formula><mml:math id="inf230"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, MMSE decline, <inline-formula><mml:math id="inf231"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, and long-range synchrony metric <inline-formula><mml:math id="inf232"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, <inline-formula><mml:math id="inf233"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub></mml:mstyle></mml:math></inline-formula>, were performed setting a total of nine events (<inline-formula><mml:math id="inf234"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>9</mml:mn></mml:mstyle></mml:math></inline-formula>). SAC-EBMs separately included long-range neural synchrony metrics in the delta-theta, alpha, and beta bands. Each EBM determined the order of nine events, thus defining ten stages (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; for the corresponding positional variance diagrams of the optimal set of <inline-formula><mml:math id="inf235"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events in the SAC-EBMs, see <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref> and <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). The resulting posterior probabilities, <inline-formula><mml:math id="inf236"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, that a subject <inline-formula><mml:math id="inf237"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> belongs to a stage <inline-formula><mml:math id="inf238"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> are shown in <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>.</p><p>For all frequency bands, around stages 5 and 6, the weighted means of PHG volume loss <inline-formula><mml:math id="inf239"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores were in the range of 1–2 and the MMSE scores were in the range of 23–27 (<xref ref-type="fig" rid="fig3">Figure 3B, F and J</xref>). Furthermore, the ratio of subjects with CDR 05 was high around stage 5 (<xref ref-type="fig" rid="fig3">Figure 3A, E1</xref>). These indicated that stage 5 best represents the onset of clinical MCI stage, and stages 1-4, where MMSE scores remain almost constant at or near 30, correspond to the preclinical stages of AD. Changes in long-range synchrony during the preclinical stages are shown as statistical bars, and the region-level changes are shown in <xref ref-type="fig" rid="fig3">Figure 3C–D, G–H, and K–L</xref>.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Trajectories of long-range neural synchrony in delta-theta, alpha, and beta-bands from SAC-EBMs.</title><p>(<bold>A, E, I</bold>) The ratio of subjects classified to each stage. The ratio was evaluated on the basis of the probabilities that each subject will be assigned to each of the ten stages. (<bold>B, F, J</bold>) Trajectories of long-range synchrony, parahippocampal gyrus (PHG) volume loss, and mini-mental state examination (MMSE) score as a function of the ten stages, showing probability-based weighted means (± SE). The asterisks (*<italic>q</italic> &lt; 0.05 and ***q &lt; 0.001, false discovery rate - FDR corrected) denote statistical significance in comparisons between stages 5 vs 1. All stage pairs with significant weighted mean differences are listed in <xref ref-type="supplementary-material" rid="supp9">Supplementary file 9</xref>. Initial and final <inline-formula><mml:math id="inf240"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores of long-range synchrony used in the SAC-EBMs were: <inline-formula><mml:math id="inf241"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>1.083</mml:mn><mml:mo>,</mml:mo><mml:mn>2.811</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf242"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>1.542</mml:mn><mml:mo>,</mml:mo><mml:mn>1.605</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf243"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>1.624</mml:mn><mml:mo>,</mml:mo><mml:mn>1.641</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> in the delta-theta, alpha, and beta bands, respectively. (<bold>C, G, K</bold>) Regional amplitude-envelope correlation (AEC) along the stages. The deviations from the regional patterns of the control group are shown. The regional patterns at the onset of the mild cognitive impairment (MCI) stage were circled with dotted lines. (<bold>D,H,L</bold>) Changes in regional patterns during the preclinical stages. Regional comparisons between two stages are shown based on non-parametric tests of weighted mean differences <inline-formula><mml:math id="inf244"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>δ</mml:mi><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>. Differences exceeding threshold (<inline-formula><mml:math id="inf245"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>q</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, FDR corrected) are displayed. The top 10 regions with significant differences are listed in <xref ref-type="supplementary-material" rid="supp10">Supplementary file 10</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Event sequences and trajectories determined by SAC-EBMs.</title><p>Sequences of nine events (<inline-formula><mml:math id="inf246"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>9</mml:mn></mml:mstyle></mml:math></inline-formula>) are displayed as filled dots. In a linear <inline-formula><mml:math id="inf247"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score model, two consecutive events for a metric are linearly interpolated. Stages are located at temporal midpoints between two consecutive event occurrence times. The combinations of frequency bands and regions circled by blue dotted lines were considered in the SAC-EBMs described in the main text. The trajectory panels circled by blue dotted lines are the same as the trajectories shown in <xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref> of the main text.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Positional variance diagrams of the <inline-formula><mml:math id="inf248"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events in SAC-EBMs.</title><p>The SAC-EBMs with the optimal sets of the <inline-formula><mml:math id="inf249"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores are shown. The labels of the <inline-formula><mml:math id="inf250"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events, E1, E2, <inline-formula><mml:math id="inf251"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo>…</mml:mo></mml:mstyle></mml:math></inline-formula>, E9, are for the parahippocampal gyrus (PHG) volume loss <inline-formula><mml:math id="inf252"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, the mini-mental state examination (MMSE) decline <inline-formula><mml:math id="inf253"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, and the magnetoencephalography (MEG)-metric <inline-formula><mml:math id="inf254"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores, respectively; <inline-formula><mml:math id="inf255"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>3</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf256"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>4</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>6</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf257"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>7</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>8</mml:mn><mml:mo>,</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mn>9</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>. Positional variance was evaluated based on the Markov chain Monte Carlo (MCMC) samples of the sequence of the optimal set of <inline-formula><mml:math id="inf258"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events, such as <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Markov chain Monte Carlo (MCMC) samples of the sequence of the optimal set of <inline-formula><mml:math id="inf259"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events in the SAC-EBM including alpha-band amplitude-envelope correlation (AEC).</title><p>A positional variance diagram for the SAC-EBM including alpha-band AEC (a upper middle panel in <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>) was calculated based on this occurrence frequency of the sequence of the <inline-formula><mml:math id="inf260"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-score events.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Posterior probabilities evaluated by the SAC-EBMs.</title><p>The posterior probabilities that a subject <inline-formula><mml:math id="inf261"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>j</mml:mi></mml:mstyle></mml:math></inline-formula> belongs to a stage <inline-formula><mml:math id="inf262"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>k</mml:mi></mml:mstyle></mml:math></inline-formula> are given by <inline-formula><mml:math id="inf263"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:msub><mml:mi>p</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>. (<italic>upper panels</italic>) Posterior probabilities in the SAC-EBM including long-range synchrony. (<italic>lower panels</italic>) Posterior probabilities in the SAC-EBM including local synchrony.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig3-figsupp4-v2.tif"/></fig></fig-group><p>Long-range synchrony in the alpha and beta bands decreased markedly during the preclinical stages of AD, preceding both PHG volume loss and MMSE decline. Specifically, between stages 1 and 4, the alpha- and beta-band long-range synchrony decreased by more than 80% of the total drop seen from stage 1 to 10. The whole brain, but especially the temporal area, was involved in these prominent preclinical changes (<xref ref-type="fig" rid="fig3">Figure 3H and L</xref>). In contrast, the trajectory of delta-theta-band long-range synchrony (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>) was almost identical to the evolution of the PHG volume loss throughout the stages, but a large variation occurred around the MCI stages (stages 5 and 6) as was found in the AC-EBM (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). There were no significant increases in region-level synchrony in delta-theta band during the preclinical stages (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), consistent with an observation seen in the AC-EBM (<xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p><p>The trajectory shapes of the PHG volume loss (almost linear) and MMSE scores (half parabola) were similar to those obtained in the AC-EBM (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). This indicates that prominent changes in alpha- and beta-band long-range synchrony during preclinical stages can be utilized to stratify the preclinical stages determined only by neurodegeneration and cognitive deficits.</p></sec><sec id="s3-6"><title>Local synchrony changes in the alpha and beta bands precede PHG volume loss and MMSE decline</title><p>SAC-EBMs including PHG volume loss, MMSE decline, and local synchrony metric <inline-formula><mml:math id="inf264"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores were performed, separately considering delta-theta-, alpha-, and beta-band local synchrony metrics. When considering delta-theta and alpha bands, around stages 6 and 7, the PHG volume loss <inline-formula><mml:math id="inf265"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores were in the range of 1–2 and the MMSE scores were in the range of 23–27 (<xref ref-type="fig" rid="fig4">Figure 4B and F</xref>), indicating that stage 6 best represents the onset of the MCI stage. Furthermore, the ratios of subjects with CDR 0.5 were high in stages 6 and 7 (<xref ref-type="fig" rid="fig4">Figure 4A and E</xref>). For the beta band, based on similar observations, stage 6 best represented the MCI stage (<xref ref-type="fig" rid="fig4">Figure 4I and J</xref>). For all frequency bands, stages 1-5, where MMSE scores remain almost constant at or near 30, corresponded to the preclinical stages of AD. The changes in local synchrony during the preclinical stages are shown as statistical bars, and the corresponding region-level changes are shown in <xref ref-type="fig" rid="fig4">Figures 4C–D, G–H and K–L</xref>.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Trajectories of local neural synchrony in delta-theta, alpha, and beta bands from SAC-EBMs.</title><p>(<bold>A, E, I</bold>) The ratio of subjects classified to each stage. (<bold>B, F, J</bold>) Trajectories of local synchrony, parahippocampal gyrus (PHG) volume loss, and mini-mental state examination (MMSE) score as a function of the 10 stages, show the weighted mean (± SE). Asterisks (***q &lt; 0.001, FDR corrected) denote statistical significance in comparisons between stages 6 vs 1. All stage pairs with significant weighted mean differences are listed in <xref ref-type="supplementary-material" rid="supp11">Supplementary file 11</xref>. The initial and final <inline-formula><mml:math id="inf266"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>-scores of local synchrony used in the SAC-EBMs were: <inline-formula><mml:math id="inf267"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow class="MJX-TeXAtom-ORD"><mml:mrow class="MJX-TeXAtom-ORD"><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>1.329</mml:mn><mml:mo>,</mml:mo><mml:mn>6.097</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, <inline-formula><mml:math id="inf268"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>1.461</mml:mn><mml:mo>,</mml:mo><mml:mn>2.866</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="inf269"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mn>1.810</mml:mn><mml:mo>,</mml:mo><mml:mn>2.784</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:math></inline-formula> in the delta-theta, alpha, and beta bands, respectively. (<bold>C, G, K</bold>) Regional spectral power along the stages. Deviations from the regional patterns of the control group are shown. The regional patterns at the onset of the mild cognitive impairment (MCI) stages were circled with dotted lines. (<bold>D, H, L</bold>) Changes in regional patterns during the preclinical stages. Regional comparisons between two stages are shown based on nonparametric tests of weighted mean differences <inline-formula><mml:math id="inf270"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>δ</mml:mi><mml:mi>z</mml:mi></mml:mstyle></mml:math></inline-formula>. Differences exceeding threshold (<inline-formula><mml:math id="inf271"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>q</mml:mi><mml:mo>&lt;</mml:mo><mml:mn>0.05</mml:mn></mml:mrow></mml:mstyle></mml:math></inline-formula>, false discovery rate - FDR corrected) are displayed. The top 10 regions with significant differences are listed in <xref ref-type="supplementary-material" rid="supp12">Supplementary file 12</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-91044-fig4-v2.tif"/></fig><p>Local synchrony in the alpha and beta bands decreased during the preclinical stages of AD, preceding both PHG volume loss and MMSE decline (<xref ref-type="fig" rid="fig4">Figure 4F and G</xref> and <xref ref-type="fig" rid="fig4">Figure 4J and K</xref>). On the contrary, the local synchrony in the delta-theta band increased, lagging the evolution of PHG volume loss (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). Specifically, the alpha-band local synchrony decreased considerably by the onset of the MCI stage, showing significant reductions in the temporal regions (<xref ref-type="fig" rid="fig4">Figure 4H</xref>) during the preclinical stages (stages 6 vs 1). It is noted that these trends were inconsistent with those found in the AC-EBM (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), especially within the preclinical stages, where there was little change found in the alpha-band local synchrony. This can be interpreted as evidence that early stages in AD progression may be better characterized by including neurophysiological markers as AD indicators. Beta-band local synchrony also decreased during the preclinical stages, preceding PHG volume loss and MMSE decline; by stage 5, the beta-band power decreased by approximately 55% of the total drop seen throughout the stages, and the reductions were observed in the whole brain (<xref ref-type="fig" rid="fig4">Figure 4L</xref>). Unlike the local synchrony trajectories in the alpha and beta bands, the local synchrony in the delta-theta band increased. The <italic>hyper-</italic>synchrony lagged the evolution of the loss of PHG volume in the preclinical stages and made a large jump around the stages 6 and 7 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p><p>As shown in the previous section, large alpha- and beta-band <italic>hypo-</italic>synchrony during the preclinical stages was also observed in long-range synchrony (<xref ref-type="fig" rid="fig3">Figure 3F and J</xref>). Notably, the decreases in the long-range metrics were much greater than those in the local metrics, especially in the early stages during the phase of preclinical AD (stages 1–3).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>We demonstrated that functional deficits of frequency-specific neural synchrony show progressive changes across AD stages. Both long-range and local neural synchrony in the alpha and beta bands, but not in the delta-theta band, was found to decrease in preclinical stages of AD, preceding neurodegeneration and cognitive decline, with more robust findings for long-range neural synchrony. These findings highlight the frequency-specific manifestations of neural synchrony in AD and that synchrony reductions in the alpha and beta bands are sensitive indices reflecting functional deficits in the earliest stages of disease progression.</p><sec id="s4-1"><title>Electrophysiological metrics of neural synchrony precede volume loss and cognitive decline</title><p>A key finding of the current study is that functional deficits as depicted by reduced neural synchrony precede structural volume loss and cognitive deficits. The EBMs on cross-sectional data clearly demonstrated that alpha- and beta-band synchrony within the inferior temporal and posterior parieto-occipital regions show significant deficits in the early disease stages–stages where volumetric and clinical deficits are still not significantly deviated from their baseline trajectory. This is consistent with the finding that functional changes occur earlier in the time course than structural changes in AD (<xref ref-type="bibr" rid="bib24">Jack et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Sperling et al., 2011</xref>).</p><p>Previous functional MRI studies have demonstrated disrupted connectivity especially between the hippocampus and several areas of the cortical default mode network (DMN) in subjects with amyloid deposition but without cognitive impairment (<xref ref-type="bibr" rid="bib55">Sperling et al., 2014</xref>). This disruption in DMN has also been observed in clinically normal older individuals without prominent brain atrophy in MTL that preserves hippocampal activity (<xref ref-type="bibr" rid="bib34">Miller et al., 2008</xref>; <xref ref-type="bibr" rid="bib20">Hedden et al., 2009</xref>), indicating altered functional connectivity during the preclinical period of AD. In contrast to such fMRI data reflecting the cascade of neural, metabolic, hemodynamic events in AD, our findings from MEG, which captures the synaptic physiology as the collective oscillatory spectra, demonstrate direct observations of AD-related altered neuronal activity.</p></sec><sec id="s4-2"><title>Frequency-specific manifestations of neural synchrony deficits along the progression of the disease</title><p>We demonstrated that oscillatory deficits and their temporal association with neurodegeneration and cognitive decline are frequency-specific. In particular, it is the alpha and beta hyposynchrony that precedes PHG atrophy and MMSE decline, whereas the delta-theta hypersynchrony does not seem to show such a precedence. This is consistent with previous findings that alpha and beta hyposynchrony is more tightly associated with tau accumulation, which is closely allied to neurodegeneration and cognitive decline (<xref ref-type="bibr" rid="bib39">Pusil et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Ranasinghe et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Ranasinghe et al., 2021</xref>). Neural hyposynchrony in the alpha and beta bands may, therefore, represent harbingers of altered synaptic physiology associated with tau accumulation in AD. In fact, in human postmortem studies, the strongest correlate of cognitive deficits in AD patients is loss of synapse (<xref ref-type="bibr" rid="bib12">DeKosky and Scheff, 1990</xref>; <xref ref-type="bibr" rid="bib59">Terry et al., 1991</xref>). A study using transgenic AD mice has also shown that synaptotoxicity is an early phenomenon in AD pathophysiology (<xref ref-type="bibr" rid="bib68">Zhou et al., 2017</xref>). In the context of fluid biomarkers to detect plasma amyloid, alpha and beta hyposynchrony can detect and quantify tau-associated neurodegenerative mechanisms, and hence may provide crucial information for early therapeutic interventions.</p><p>Previous studies have also shown that delta-theta oscillatory activity increases in AD and is strongly associated with amyloid accumulation (<xref ref-type="bibr" rid="bib41">Ranasinghe et al., 2020</xref>; <xref ref-type="bibr" rid="bib44">Ranasinghe et al., 2022b</xref>). In particular, increased delta-theta activity is a robust signal in individuals who are amyloid positive and cognitively unimpaired as well as those who harbor APOE-<inline-formula><mml:math id="inf272"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mi>ϵ</mml:mi><mml:mn>4</mml:mn></mml:mstyle></mml:math></inline-formula> allele and an increased risk of AD (<xref ref-type="bibr" rid="bib11">Cuesta et al., 2015</xref>; <xref ref-type="bibr" rid="bib35">Nakamura et al., 2018</xref>). These previous findings indicate that delta-theta hypersynchrony is an early change in the AD spectrum and may even precede neurodegeneration and cognitive deficits. However, in the current results, the trajectory of the delta-theta hypersynchrony was identical to or lagged that of the PHG volume loss. This apparent controversy may be due to the possibility that oscillatory changes in the delta-theta band are more closely related to amyloid accumulations in AD, which become saturated early in the disease course and have a poor association with neurodegeneration and cognitive trajectories. It would be worth exploring how the trajectory of early saturated variables may be captured by EBM approaches.</p></sec><sec id="s4-3"><title>Distinction between long-range and local synchrony deficits in disease progression</title><p>The decrease in alpha and beta-band long-range metrics in the preclinical stages was much greater than that in the local metrics. This is consistent with the fact that AD-related abnormal brain activities are observed as disruptions of functional networks. Long-range cross-regional metrics, such as AECs, directly capture network disruptions involving all brain regions, while local metrics capture features of individual regions. From the definition, local synchrony describes collective neuronal oscillations in each local region, and thus the change along AD progression may depend mainly on long-term, slowly changing regional neuronal loss. On the other hand, long-range synchrony describes temporal coherence amongst regional collective neuronal oscillations and is vulnerable to altered neuronal oscillations. Therefore, long-range metrics are more sensitive to abnormal rhythms, collecting local abnormalities.</p><p>Preclinical neurophysiological markers that indicate the pathophysiology of AD are clinically important but have not been established. Aβ accumulation in preclinical stages is just a necessary condition for AD, and additional preclinical markers are required to fully predict the progression of AD. From this point of view, the present study indicates that alpha- and beta-band MEG metrics, especially long-range synchrony metrics (AEC), which were found to be sensitive to preclinical stages, could be promising candidates as additional markers.</p></sec><sec id="s4-4"><title>Limitations</title><p>A limitation of the current study is that there were differences in age between controls and AD patients. Although we adjusted the age of each metric using GLMs, age trajectories in neurophysiological measures have been reported to be nonlinear even in healthy aging (<xref ref-type="bibr" rid="bib46">Sahoo et al., 2020</xref>). Age-related changes in brain atrophy have also been reported to follow a nonlinear time course depending on the brain areas (<xref ref-type="bibr" rid="bib10">Coupé et al., 2019</xref>). These studies indicate that it may be better to employ a non-linear method beyond GLM to perfectly correct aging effects.</p><p>Another limitation is that we have not performed independent validations of the predicted trajectories and also have not examined the heterogeneity in AD progression, although we clarified for the first time the time courses of MEG neurophysiological metrics in AD progression. In fact, AD is a heterogeneous multifactorial disorder with various pathobiological subtypes (<xref ref-type="bibr" rid="bib27">Jellinger, 2022</xref>). In this context, an EBM called <italic>Subtype and Stage Inference</italic> (SuStaIn) capable of capturing spatio-temporal heterogeneity of diseases (<xref ref-type="bibr" rid="bib67">Young et al., 2018</xref>) has been proposed to subtyping neurodegenerative diseases including typical AD and has been applied to find different spatio-temporal trajectories of longitudinal tau-PET data in AD (<xref ref-type="bibr" rid="bib62">Vogel et al., 2021</xref>). Since oscillatory rhythms are thought to depend on AD subtypes (<xref ref-type="bibr" rid="bib40">Ranasinghe et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Ranasinghe et al., 2022a</xref>), an extended trajectory analysis considering spatial and temporal variations of the MEG/EEG metrics is warranted in the future, and such analyses would provide distinct neurophysiological trajectories depending on AD subtypes. As a validation of the predicted trajectories, it would be necessary to investigate whether the predicted EBM stages are reliable and predictive of conversions (e.g. from control to MCI) while taking the AD subtypes into account.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>KK is a full-time employee of Ricoh Company, Ltd</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>HM is a full-time employee of Ricoh Company, Ltd</p></fn><fn fn-type="COI-statement" id="conf4"><p>KS is an employee of Signal Analysis Inc</p></fn><fn fn-type="COI-statement" id="conf5"><p>SSN is a scientific consultant to MEGIN Inc and a Medical Strategy Adviser to Hippoclinic Inc. He served on the scientific advisory board for Rune Labs Inc from 2019-2022. He was the recipient of an industry contract from Ricoh MEG USA Inc</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Software, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Resources, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Software, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Resources, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Resources, Supervision, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Resources, Data curation, Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Informed consent was obtained from all participants and the study was approved by the Institutional Review Board (IRB) at UCSF (UCSF-IRB 10-02245).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Demographics and Neuropsychological assessments.</title></caption><media xlink:href="elife-91044-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>The 94 cortical/subcortical anatomical regions included in the Automated Anatomical Labeling 3 (AAL3) atlas.</title></caption><media xlink:href="elife-91044-supp2-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Direct evaluation of the data likelihoods for all possible -score event sequences in the Atrophy-Cognition EBM (AC-EBM).</title></caption><media xlink:href="elife-91044-supp3-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>Top 10 regions with significant group differences in gray matter (GM) volumes comparison between Alzheimer’s disease (AD) patients and controls.</title></caption><media xlink:href="elife-91044-supp4-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp5"><label>Supplementary file 5.</label><caption><title>Top regions with significant group differences in long-range synchrony between patients with Alzheimer’s disease (AD) and controls.</title></caption><media xlink:href="elife-91044-supp5-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp6"><label>Supplementary file 6.</label><caption><title>Top 10 regions with significant group differences in local synchrony between patients with Alzheimer’s disease (AD) and controls.</title></caption><media xlink:href="elife-91044-supp6-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp7"><label>Supplementary file 7.</label><caption><title>Top regions with significant weighted mean differences (false discovery rate, FDR corrected) in long-range synchrony between stages 4 and 1 (<xref ref-type="fig" rid="fig2">Figure 2E</xref> in the main text).</title></caption><media xlink:href="elife-91044-supp7-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp8"><label>Supplementary file 8.</label><caption><title>Top regions with significant weighted mean differences (false discovery rate, FDR corrected) in local synchrony between stages 4 and 1 (Figure 2F in the main text).</title></caption><media xlink:href="elife-91044-supp8-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp9"><label>Supplementary file 9.</label><caption><title>Pairs of stages with significant weighted-mean differences.</title></caption><media xlink:href="elife-91044-supp9-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp10"><label>Supplementary file 10.</label><caption><title>Top regions with significant weighted-mean differences (false discovery rate, FDR corrected) in regional variations of long-range synchrony during preclinical stages (stages 5 vs 1).</title></caption><media xlink:href="elife-91044-supp10-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp11"><label>Supplementary file 11.</label><caption><title>Pairs of stages with significant weighted-mean differences .</title></caption><media xlink:href="elife-91044-supp11-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp12"><label>Supplementary file 12.</label><caption><title>Top regions with significant weighted-mean differences (false discovery rate, FDR corrected) in regional variations of local synchrony during the preclinical stages (stages 6 vs 1) [Figure 4D, H, L in the main text].</title></caption><media xlink:href="elife-91044-supp12-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-91044-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>The processed datasets including PHG volumes, MMSE scores, scalar and regional MEG metrics, and a set of MATLAB scripts for reproducing all results and figures in the manuscript are available at OSF (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17605/OSF.IO/PD4H9">https://doi.org/10.17605/OSF.IO/PD4H9</ext-link>). Any interested researcher can access the source data for all original figures in the manuscript by running the MATLAB scripts freely under the conditions of a CC0 license. De-identified MEG and MRI data are also shared on the OSF website. Please forward any correspondence and material requests to kamalini.ranasinghe@ucsf.edu or contact srikantan.nagarajan@ucsf.edu .</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Kudo</surname><given-names>K</given-names></name><name><surname>Ranasinghe</surname><given-names>K</given-names></name><name><surname>Nagarajan</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Neurophysiological trajectories in AD progression</data-title><source>Open Science Framework</source><pub-id pub-id-type="doi">10.17605/OSF.IO/PD4H9</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank all study participants for their support for our research.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablin</surname><given-names>P</given-names></name><name><surname>Cardoso</surname><given-names>JF</given-names></name><name><surname>Gramfort</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Faster independent component analysis by preconditioning with hessian approximations</article-title><source>IEEE Transactions on Signal Processing</source><volume>66</volume><fpage>4040</fpage><lpage>4049</lpage><pub-id pub-id-type="doi">10.1109/TSP.2018.2844203</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahnaou</surname><given-names>A</given-names></name><name><surname>Moechars</surname><given-names>D</given-names></name><name><surname>Raeymaekers</surname><given-names>L</given-names></name><name><surname>Biermans</surname><given-names>R</given-names></name><name><surname>Manyakov</surname><given-names>NV</given-names></name><name><surname>Bottelbergs</surname><given-names>A</given-names></name><name><surname>Wintmolders</surname><given-names>C</given-names></name><name><surname>Van Kolen</surname><given-names>K</given-names></name><name><surname>Van De Casteele</surname><given-names>T</given-names></name><name><surname>Kemp</surname><given-names>JA</given-names></name><name><surname>Drinkenburg</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Emergence of early alterations in network oscillations and functional connectivity in a tau seeding mouse model of Alzheimer’s disease pathology</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>14189</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-13839-6</pub-id><pub-id pub-id-type="pmid">29079799</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Gamst</surname><given-names>A</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Snyder</surname><given-names>PJ</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Thies</surname><given-names>B</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>7</volume><fpage>270</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.008</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title><source>Journal of the Royal Statistical Society</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briels</surname><given-names>CT</given-names></name><name><surname>Schoonhoven</surname><given-names>DN</given-names></name><name><surname>Stam</surname><given-names>CJ</given-names></name><name><surname>de Waal</surname><given-names>H</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Gouw</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Reproducibility of EEG functional connectivity in Alzheimer’s disease</article-title><source>Alzheimer’s Research &amp; Therapy</source><volume>12</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1186/s13195-020-00632-3</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briels</surname><given-names>CT</given-names></name><name><surname>Stam</surname><given-names>CJ</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Bruins</surname><given-names>S</given-names></name><name><surname>Lues</surname><given-names>I</given-names></name><name><surname>Gouw</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer’s disease</article-title><source>Clinical Neurophysiology</source><volume>131</volume><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2019.09.014</pub-id><pub-id pub-id-type="pmid">31759193</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busche</surname><given-names>MA</given-names></name><name><surname>Eichhoff</surname><given-names>G</given-names></name><name><surname>Adelsberger</surname><given-names>H</given-names></name><name><surname>Abramowski</surname><given-names>D</given-names></name><name><surname>Wiederhold</surname><given-names>KH</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Staufenbiel</surname><given-names>M</given-names></name><name><surname>Konnerth</surname><given-names>A</given-names></name><name><surname>Garaschuk</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease</article-title><source>Science</source><volume>321</volume><fpage>1686</fpage><lpage>1689</lpage><pub-id pub-id-type="doi">10.1126/science.1162844</pub-id><pub-id pub-id-type="pmid">18802001</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busche</surname><given-names>MA</given-names></name><name><surname>Wegmann</surname><given-names>S</given-names></name><name><surname>Dujardin</surname><given-names>S</given-names></name><name><surname>Commins</surname><given-names>C</given-names></name><name><surname>Schiantarelli</surname><given-names>J</given-names></name><name><surname>Klickstein</surname><given-names>N</given-names></name><name><surname>Kamath</surname><given-names>TV</given-names></name><name><surname>Carlson</surname><given-names>GA</given-names></name><name><surname>Nelken</surname><given-names>I</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo</article-title><source>Nature Neuroscience</source><volume>22</volume><fpage>57</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/s41593-018-0289-8</pub-id><pub-id pub-id-type="pmid">30559471</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colclough</surname><given-names>GL</given-names></name><name><surname>Woolrich</surname><given-names>MW</given-names></name><name><surname>Tewarie</surname><given-names>PK</given-names></name><name><surname>Brookes</surname><given-names>MJ</given-names></name><name><surname>Quinn</surname><given-names>AJ</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>How reliable are MEG resting-state connectivity metrics?</article-title><source>NeuroImage</source><volume>138</volume><fpage>284</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.05.070</pub-id><pub-id pub-id-type="pmid">27262239</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coupé</surname><given-names>P</given-names></name><name><surname>Manjón</surname><given-names>JV</given-names></name><name><surname>Lanuza</surname><given-names>E</given-names></name><name><surname>Catheline</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Lifespan changes of the human brain in alzheimer’s disease</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>3998</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-39809-8</pub-id><pub-id pub-id-type="pmid">30850617</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuesta</surname><given-names>P</given-names></name><name><surname>Garcés</surname><given-names>P</given-names></name><name><surname>Castellanos</surname><given-names>NP</given-names></name><name><surname>López</surname><given-names>ME</given-names></name><name><surname>Aurtenetxe</surname><given-names>S</given-names></name><name><surname>Bajo</surname><given-names>R</given-names></name><name><surname>Pineda-Pardo</surname><given-names>JA</given-names></name><name><surname>Bruña</surname><given-names>R</given-names></name><name><surname>Marín</surname><given-names>AG</given-names></name><name><surname>Delgado</surname><given-names>M</given-names></name><name><surname>Barabash</surname><given-names>A</given-names></name><name><surname>Ancín</surname><given-names>I</given-names></name><name><surname>Cabranes</surname><given-names>JA</given-names></name><name><surname>Fernandez</surname><given-names>A</given-names></name><name><surname>del Pozo</surname><given-names>F</given-names></name><name><surname>Sancho</surname><given-names>M</given-names></name><name><surname>Marcos</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Maestú</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Influence of the apoe ε4 allele and mild cognitive impairment diagnosis in the disruption of the meg resting state functional connectivity in sources space</article-title><source>Journal of Alzheimer’s Disease</source><volume>44</volume><fpage>493</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.3233/JAD-141872</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Scheff</surname><given-names>SW</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity</article-title><source>Annals of Neurology</source><volume>27</volume><fpage>457</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1002/ana.410270502</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeTure</surname><given-names>MA</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The neuropathological diagnosis of Alzheimer’s disease</article-title><source>Molecular Neurodegeneration</source><volume>14</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1186/s13024-019-0333-5</pub-id><pub-id pub-id-type="pmid">31375134</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Aisen</surname><given-names>P</given-names></name><name><surname>Andrieu</surname><given-names>S</given-names></name><name><surname>Bakardjian</surname><given-names>H</given-names></name><name><surname>Benali</surname><given-names>H</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Broich</surname><given-names>K</given-names></name><name><surname>Cavedo</surname><given-names>E</given-names></name><name><surname>Crutch</surname><given-names>S</given-names></name><name><surname>Dartigues</surname><given-names>J</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Epelbaum</surname><given-names>S</given-names></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Genthon</surname><given-names>R</given-names></name><name><surname>Gouw</surname><given-names>AA</given-names></name><name><surname>Habert</surname><given-names>M</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Kivipelto</surname><given-names>M</given-names></name><name><surname>Lista</surname><given-names>S</given-names></name><name><surname>Molinuevo</surname><given-names>J</given-names></name><name><surname>O’Bryant</surname><given-names>SE</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name><name><surname>Rowe</surname><given-names>C</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Teichmann</surname><given-names>M</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria</article-title><source>Alzheimer’s &amp; Dementia</source><volume>12</volume><fpage>292</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2016.02.002</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echávarri</surname><given-names>C</given-names></name><name><surname>Aalten</surname><given-names>P</given-names></name><name><surname>Uylings</surname><given-names>HBM</given-names></name><name><surname>Jacobs</surname><given-names>HIL</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Gronenschild</surname><given-names>EHBM</given-names></name><name><surname>Verhey</surname><given-names>FRJ</given-names></name><name><surname>Burgmans</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease</article-title><source>Brain Structure &amp; Function</source><volume>215</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s00429-010-0283-8</pub-id><pub-id pub-id-type="pmid">20957494</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engels</surname><given-names>MMA</given-names></name><name><surname>Hillebrand</surname><given-names>A</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Stam</surname><given-names>CJ</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>van Straaten</surname><given-names>ECW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Slowing of hippocampal activity correlates with cognitive decline in early onset alzheimer’s disease: an meg study with virtual electrodes</article-title><source>Frontiers in Human Neuroscience</source><volume>10</volume><elocation-id>238</elocation-id><pub-id pub-id-type="doi">10.3389/fnhum.2016.00238</pub-id><pub-id pub-id-type="pmid">27242496</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández</surname><given-names>A</given-names></name><name><surname>Hornero</surname><given-names>R</given-names></name><name><surname>Mayo</surname><given-names>A</given-names></name><name><surname>Poza</surname><given-names>J</given-names></name><name><surname>Gil-Gregorio</surname><given-names>P</given-names></name><name><surname>Ortiz</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>MEG spectral profile in Alzheimer’s disease and mild cognitive impairment</article-title><source>Clinical Neurophysiology</source><volume>117</volume><fpage>306</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2005.10.017</pub-id><pub-id pub-id-type="pmid">16386951</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonteijn</surname><given-names>HM</given-names></name><name><surname>Modat</surname><given-names>M</given-names></name><name><surname>Clarkson</surname><given-names>MJ</given-names></name><name><surname>Barnes</surname><given-names>J</given-names></name><name><surname>Lehmann</surname><given-names>M</given-names></name><name><surname>Hobbs</surname><given-names>NZ</given-names></name><name><surname>Scahill</surname><given-names>RI</given-names></name><name><surname>Tabrizi</surname><given-names>SJ</given-names></name><name><surname>Ourselin</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Alexander</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An event-based model for disease progression and its application in familial Alzheimer’s disease and Huntington’s disease</article-title><source>NeuroImage</source><volume>60</volume><fpage>1880</fpage><lpage>1889</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.01.062</pub-id><pub-id pub-id-type="pmid">22281676</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Gaser</surname><given-names>C</given-names></name><name><surname>Dahnke</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>PM</given-names></name><name><surname>Kurth</surname><given-names>F</given-names></name><name><surname>Luders</surname><given-names>E</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><year iso-8601-date="2022">2022</year><article-title>CAT – A Computational Anatomy Toolbox for the Analysis of Structural MRI Data</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2022.06.11.495736</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedden</surname><given-names>T</given-names></name><name><surname>Van Dijk</surname><given-names>KRA</given-names></name><name><surname>Becker</surname><given-names>JA</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Disruption of functional connectivity in clinically normal older adults harboring amyloid burden</article-title><source>The Journal of Neuroscience</source><volume>29</volume><fpage>12686</fpage><lpage>12694</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3189-09.2009</pub-id><pub-id pub-id-type="pmid">19812343</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hipp</surname><given-names>JF</given-names></name><name><surname>Hawellek</surname><given-names>DJ</given-names></name><name><surname>Corbetta</surname><given-names>M</given-names></name><name><surname>Siegel</surname><given-names>M</given-names></name><name><surname>Engel</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Large-scale cortical correlation structure of spontaneous oscillatory activity</article-title><source>Nature Neuroscience</source><volume>15</volume><fpage>884</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1038/nn.3101</pub-id><pub-id pub-id-type="pmid">22561454</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>Y</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Nemoto</surname><given-names>K</given-names></name><name><surname>Ohnishi</surname><given-names>T</given-names></name><name><surname>Hirao</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>F</given-names></name><name><surname>Asada</surname><given-names>T</given-names></name><name><surname>Iwabuchi</surname><given-names>S</given-names></name><name><surname>Samejima</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Voxel-based morphometry to discriminate early Alzheimer’s disease from controls</article-title><source>Neuroscience Letters</source><volume>382</volume><fpage>269</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2005.03.038</pub-id><pub-id pub-id-type="pmid">15925102</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>LE</given-names></name><name><surname>Henson</surname><given-names>RN</given-names></name><name><surname>Pereda</surname><given-names>E</given-names></name><name><surname>Bruña</surname><given-names>R</given-names></name><name><surname>López‐Sanz</surname><given-names>D</given-names></name><name><surname>Quinn</surname><given-names>AJ</given-names></name><name><surname>Woolrich</surname><given-names>MW</given-names></name><name><surname>Nobre</surname><given-names>AC</given-names></name><name><surname>Rowe</surname><given-names>JB</given-names></name><name><surname>Maestú</surname><given-names>F</given-names></name><collab>the BioFIND Working Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Biomagnetic biomarkers for dementia: A pilot multicentre study with A recommended methodological framework for magnetoencephalography</article-title><source>Alzheimer’s &amp; Dementia</source><volume>11</volume><fpage>450</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.dadm.2019.04.009</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Wiste</surname><given-names>HJ</given-names></name><name><surname>Vemuri</surname><given-names>P</given-names></name><name><surname>Weigand</surname><given-names>SD</given-names></name><name><surname>Senjem</surname><given-names>ML</given-names></name><name><surname>Zeng</surname><given-names>G</given-names></name><name><surname>Bernstein</surname><given-names>MA</given-names></name><name><surname>Gunter</surname><given-names>JL</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease</article-title><source>Brain</source><volume>133</volume><fpage>3336</fpage><lpage>3348</lpage><pub-id pub-id-type="doi">10.1093/brain/awq277</pub-id><pub-id pub-id-type="pmid">20935035</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Vemuri</surname><given-names>P</given-names></name><name><surname>Wiste</surname><given-names>HJ</given-names></name><name><surname>Weigand</surname><given-names>SD</given-names></name><name><surname>Lesnick</surname><given-names>TG</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><name><surname>Donohue</surname><given-names>MC</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers</article-title><source>The Lancet Neurology</source><volume>12</volume><fpage>207</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70291-0</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Dunn</surname><given-names>B</given-names></name><name><surname>Haeberlein</surname><given-names>SB</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Jagust</surname><given-names>W</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Karlawish</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Montine</surname><given-names>T</given-names></name><name><surname>Phelps</surname><given-names>C</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name><name><surname>Rowe</surname><given-names>CC</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><name><surname>Snyder</surname><given-names>HM</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Elliott</surname><given-names>C</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Ryan</surname><given-names>L</given-names></name><name><surname>Silverberg</surname><given-names>N</given-names></name><collab>Contributors</collab></person-group><year iso-8601-date="2018">2018</year><article-title>NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>14</volume><fpage>535</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmid">29653606</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jellinger</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Recent update on the heterogeneity of the Alzheimer’s disease spectrum</article-title><source>Journal of Neural Transmission</source><volume>129</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s00702-021-02449-2</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>EEG dynamics in patients with Alzheimer’s disease</article-title><source>Clinical Neurophysiology</source><volume>115</volume><fpage>1490</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2004.01.001</pub-id><pub-id pub-id-type="pmid">15203050</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koelewijn</surname><given-names>L</given-names></name><name><surname>Bompas</surname><given-names>A</given-names></name><name><surname>Tales</surname><given-names>A</given-names></name><name><surname>Brookes</surname><given-names>MJ</given-names></name><name><surname>Muthukumaraswamy</surname><given-names>SD</given-names></name><name><surname>Bayer</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alzheimer’s disease disrupts alpha and beta-band resting-state oscillatory network connectivity</article-title><source>Clinical Neurophysiology</source><volume>128</volume><fpage>2347</fpage><lpage>2357</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2017.04.018</pub-id><pub-id pub-id-type="pmid">28571910</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Mizumura</surname><given-names>S</given-names></name><name><surname>Nemoto</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>F</given-names></name><name><surname>Imabayashi</surname><given-names>E</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Asada</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease</article-title><source>AJNR. American Journal of Neuroradiology</source><volume>33</volume><fpage>1109</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.3174/ajnr.A2935</pub-id><pub-id pub-id-type="pmid">22300935</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MRI morphometry in Alzheimer’s disease</article-title><source>Ageing Research Reviews</source><volume>30</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2016.01.003</pub-id><pub-id pub-id-type="pmid">26812213</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKhann</surname><given-names>GM</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Kawas</surname><given-names>CH</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Koroshetz</surname><given-names>WJ</given-names></name><name><surname>Manly</surname><given-names>JJ</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Mohs</surname><given-names>RC</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Thies</surname><given-names>B</given-names></name><name><surname>Weintraub</surname><given-names>S</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>7</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.005</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meghdadi</surname><given-names>AH</given-names></name><name><surname>Stevanović Karić</surname><given-names>M</given-names></name><name><surname>McConnell</surname><given-names>M</given-names></name><name><surname>Rupp</surname><given-names>G</given-names></name><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Hamilton</surname><given-names>J</given-names></name><name><surname>Salat</surname><given-names>D</given-names></name><name><surname>Berka</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment</article-title><source>PLOS ONE</source><volume>16</volume><elocation-id>e0244180</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0244180</pub-id><pub-id pub-id-type="pmid">33544703</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>SL</given-names></name><name><surname>Celone</surname><given-names>K</given-names></name><name><surname>DePeau</surname><given-names>K</given-names></name><name><surname>Diamond</surname><given-names>E</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name><name><surname>Rentz</surname><given-names>D</given-names></name><name><surname>Pihlajamäki</surname><given-names>M</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation</article-title><source>PNAS</source><volume>105</volume><fpage>2181</fpage><lpage>2186</lpage><pub-id pub-id-type="doi">10.1073/pnas.0706818105</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>A</given-names></name><name><surname>Cuesta</surname><given-names>P</given-names></name><name><surname>Fernández</surname><given-names>A</given-names></name><name><surname>Arahata</surname><given-names>Y</given-names></name><name><surname>Iwata</surname><given-names>K</given-names></name><name><surname>Kuratsubo</surname><given-names>I</given-names></name><name><surname>Bundo</surname><given-names>M</given-names></name><name><surname>Hattori</surname><given-names>H</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Fukuda</surname><given-names>K</given-names></name><name><surname>Washimi</surname><given-names>Y</given-names></name><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Diers</surname><given-names>K</given-names></name><name><surname>Bajo</surname><given-names>R</given-names></name><name><surname>Maestú</surname><given-names>F</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease</article-title><source>Brain</source><volume>141</volume><fpage>1470</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1093/brain/awy044</pub-id><pub-id pub-id-type="pmid">29522156</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolte</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The magnetic lead field theorem in the quasi-static approximation and its use for magnetoencephalography forward calculation in realistic volume conductors</article-title><source>Physics in Medicine and Biology</source><volume>48</volume><fpage>3637</fpage><lpage>3652</lpage><pub-id pub-id-type="doi">10.1088/0031-9155/48/22/002</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oostenveld</surname><given-names>R</given-names></name><name><surname>Fries</surname><given-names>P</given-names></name><name><surname>Maris</surname><given-names>E</given-names></name><name><surname>Schoffelen</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>FieldTrip: Open source software for advanced analysis of MEG, EEG, and invasive electrophysiological data</article-title><source>Computational Intelligence and Neuroscience</source><volume>2011</volume><elocation-id>156869</elocation-id><pub-id pub-id-type="doi">10.1155/2011/156869</pub-id><pub-id pub-id-type="pmid">21253357</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Penny</surname><given-names>WD</given-names></name><name><surname>Friston</surname><given-names>KJ</given-names></name><name><surname>Ashburner</surname><given-names>JT</given-names></name><name><surname>Kiebel</surname><given-names>SJ</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2011">2011</year><source>Statistical Parametric Mapping: The Analysis of Functional Brain Images</source><publisher-name>Elsevier</publisher-name></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pusil</surname><given-names>S</given-names></name><name><surname>López</surname><given-names>ME</given-names></name><name><surname>Cuesta</surname><given-names>P</given-names></name><name><surname>Bruña</surname><given-names>R</given-names></name><name><surname>Pereda</surname><given-names>E</given-names></name><name><surname>Maestú</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hypersynchronization in mild cognitive impairment: the “X” model</article-title><source>Brain</source><volume>142</volume><fpage>3936</fpage><lpage>3950</lpage><pub-id pub-id-type="doi">10.1093/brain/awz320</pub-id><pub-id pub-id-type="pmid">31633176</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranasinghe</surname><given-names>KG</given-names></name><name><surname>Hinkley</surname><given-names>LB</given-names></name><name><surname>Beagle</surname><given-names>AJ</given-names></name><name><surname>Mizuiri</surname><given-names>D</given-names></name><name><surname>Honma</surname><given-names>SM</given-names></name><name><surname>Welch</surname><given-names>AE</given-names></name><name><surname>Hubbard</surname><given-names>I</given-names></name><name><surname>Mandelli</surname><given-names>ML</given-names></name><name><surname>Miller</surname><given-names>ZA</given-names></name><name><surname>Garrett</surname><given-names>C</given-names></name><name><surname>La</surname><given-names>A</given-names></name><name><surname>Boxer</surname><given-names>AL</given-names></name><name><surname>Houde</surname><given-names>JF</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Vossel</surname><given-names>KA</given-names></name><name><surname>Gorno-Tempini</surname><given-names>ML</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Distinct spatiotemporal patterns of neuronal functional connectivity in primary progressive aphasia variants</article-title><source>Brain</source><volume>140</volume><fpage>2737</fpage><lpage>2751</lpage><pub-id pub-id-type="doi">10.1093/brain/awx217</pub-id><pub-id pub-id-type="pmid">28969381</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranasinghe</surname><given-names>KG</given-names></name><name><surname>Cha</surname><given-names>J</given-names></name><name><surname>Iaccarino</surname><given-names>L</given-names></name><name><surname>Hinkley</surname><given-names>LB</given-names></name><name><surname>Beagle</surname><given-names>AJ</given-names></name><name><surname>Pham</surname><given-names>J</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name><name><surname>Vossel</surname><given-names>KA</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neurophysiological signatures in Alzheimer’s disease are distinctly associated with TAU, amyloid-β accumulation, and cognitive decline</article-title><source>Science Translational Medicine</source><volume>12</volume><elocation-id>eaaz4069</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaz4069</pub-id><pub-id pub-id-type="pmid">32161102</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranasinghe</surname><given-names>KG</given-names></name><name><surname>Petersen</surname><given-names>C</given-names></name><name><surname>Kudo</surname><given-names>K</given-names></name><name><surname>Mizuiri</surname><given-names>D</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name><name><surname>Gorno‐Tempini</surname><given-names>ML</given-names></name><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Spina</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Vossel</surname><given-names>K</given-names></name><name><surname>Grinberg</surname><given-names>LT</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reduced synchrony in alpha oscillations during life predicts <italic>post mortem</italic> neurofibrillary tangle density in early‐onset and atypical Alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>17</volume><fpage>2009</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1002/alz.12349</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranasinghe</surname><given-names>KG</given-names></name><name><surname>Kudo</surname><given-names>K</given-names></name><name><surname>Hinkley</surname><given-names>L</given-names></name><name><surname>Beagle</surname><given-names>A</given-names></name><name><surname>Lerner</surname><given-names>H</given-names></name><name><surname>Mizuiri</surname><given-names>D</given-names></name><name><surname>Findlay</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Gorno-Tempini</surname><given-names>ML</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name><name><surname>Garcia</surname><given-names>PA</given-names></name><name><surname>Kirsch</surname><given-names>HE</given-names></name><name><surname>Vossel</surname><given-names>K</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer’s disease</article-title><source>Brain</source><volume>145</volume><fpage>744</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1093/brain/awab442</pub-id><pub-id pub-id-type="pmid">34919638</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranasinghe</surname><given-names>KG</given-names></name><name><surname>Verma</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Kudo</surname><given-names>K</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Lerner</surname><given-names>H</given-names></name><name><surname>Mizuiri</surname><given-names>D</given-names></name><name><surname>Strom</surname><given-names>A</given-names></name><name><surname>Iaccarino</surname><given-names>L</given-names></name><name><surname>La Joie</surname><given-names>R</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Gorno-Tempini</surname><given-names>ML</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Vossel</surname><given-names>K</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name><name><surname>Raj</surname><given-names>A</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Altered excitatory and inhibitory neuronal subpopulation parameters are distinctly associated with tau and amyloid in Alzheimer’s disease</article-title><source>eLife</source><volume>11</volume><elocation-id>e77850</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.77850</pub-id><pub-id pub-id-type="pmid">35616532</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolls</surname><given-names>ET</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Lin</surname><given-names>CP</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Joliot</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Automated anatomical labelling atlas 3</article-title><source>NeuroImage</source><volume>206</volume><elocation-id>116189</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.116189</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sahoo</surname><given-names>B</given-names></name><name><surname>Pathak</surname><given-names>A</given-names></name><name><surname>Deco</surname><given-names>G</given-names></name><name><surname>Banerjee</surname><given-names>A</given-names></name><name><surname>Roy</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lifespan associated global patterns of coherent neural communication</article-title><source>NeuroImage</source><volume>216</volume><elocation-id>116824</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.116824</pub-id><pub-id pub-id-type="pmid">32289459</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scahill</surname><given-names>RI</given-names></name><name><surname>Schott</surname><given-names>JM</given-names></name><name><surname>Stevens</surname><given-names>JM</given-names></name><name><surname>Rossor</surname><given-names>MN</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Mapping the evolution of regional atrophy in Alzheimer’s disease: Unbiased analysis of fluid-registered serial MRI</article-title><source>PNAS</source><volume>99</volume><fpage>4703</fpage><lpage>4707</lpage><pub-id pub-id-type="doi">10.1073/pnas.052587399</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoonhoven</surname><given-names>DN</given-names></name><name><surname>Briels</surname><given-names>CT</given-names></name><name><surname>Hillebrand</surname><given-names>A</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Stam</surname><given-names>CJ</given-names></name><name><surname>Gouw</surname><given-names>AA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease</article-title><source>Alzheimer’s Research &amp; Therapy</source><volume>14</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1186/s13195-022-00970-4</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekihara</surname><given-names>K</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name><name><surname>Poeppel</surname><given-names>D</given-names></name><name><surname>Marantz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Asymptotic SNR of scalar and vector minimum-variance beamformers for neuromagnetic source reconstruction</article-title><source>IEEE Transactions on Bio-Medical Engineering</source><volume>51</volume><fpage>1726</fpage><lpage>1734</lpage><pub-id pub-id-type="doi">10.1109/TBME.2004.827926</pub-id><pub-id pub-id-type="pmid">15490820</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sekihara</surname><given-names>K</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2008">2008</year><source>Adaptive Spatial Filters for Electromagnetic Brain Imaging</source><publisher-name>Springer Science &amp; Business Media</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-540-79370-0</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sekihara</surname><given-names>K</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2015">2015</year><source>Electromagnetic Brain Imaging: A Bayesian Perspective</source><publisher-loc>Cham</publisher-loc><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-3-319-14947-9</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekihara</surname><given-names>K</given-names></name><name><surname>Kawabata</surname><given-names>Y</given-names></name><name><surname>Ushio</surname><given-names>S</given-names></name><name><surname>Sumiya</surname><given-names>S</given-names></name><name><surname>Kawabata</surname><given-names>S</given-names></name><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Nagarajan</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dual signal subspace projection (DSSP): a novel algorithm for removing large interference in biomagnetic measurements</article-title><source>Journal of Neural Engineering</source><volume>13</volume><elocation-id>036007</elocation-id><pub-id pub-id-type="doi">10.1088/1741-2560/13/3/036007</pub-id><pub-id pub-id-type="pmid">27064933</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Alzheimer’s disease is a synaptic failure</article-title><source>Science</source><volume>298</volume><fpage>789</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1126/science.1074069</pub-id><pub-id pub-id-type="pmid">12399581</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Beckett</surname><given-names>LA</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Park</surname><given-names>DC</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Rowe</surname><given-names>CC</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Thies</surname><given-names>B</given-names></name><name><surname>Morrison‐Bogorad</surname><given-names>M</given-names></name><name><surname>Wagster</surname><given-names>MV</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>7</volume><fpage>280</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2011.03.003</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sperling</surname><given-names>R</given-names></name><name><surname>Mormino</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The evolution of preclinical Alzheimer’s disease: implications for prevention trials</article-title><source>Neuron</source><volume>84</volume><fpage>608</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.10.038</pub-id><pub-id pub-id-type="pmid">25442939</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The intersection of amyloid beta and tau at synapses in Alzheimer’s disease</article-title><source>Neuron</source><volume>82</volume><fpage>756</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.05.004</pub-id><pub-id pub-id-type="pmid">24853936</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stam</surname><given-names>CJ</given-names></name><name><surname>Jones</surname><given-names>BF</given-names></name><name><surname>Manshanden</surname><given-names>I</given-names></name><name><surname>van Cappellen van Walsum</surname><given-names>AM</given-names></name><name><surname>Montez</surname><given-names>T</given-names></name><name><surname>Verbunt</surname><given-names>JPA</given-names></name><name><surname>de Munck</surname><given-names>JC</given-names></name><name><surname>van Dijk</surname><given-names>BW</given-names></name><name><surname>Berendse</surname><given-names>HW</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer’s disease</article-title><source>NeuroImage</source><volume>32</volume><fpage>1335</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.05.033</pub-id><pub-id pub-id-type="pmid">16815039</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teipel</surname><given-names>SJ</given-names></name><name><surname>Pruessner</surname><given-names>JC</given-names></name><name><surname>Faltraco</surname><given-names>F</given-names></name><name><surname>Born</surname><given-names>C</given-names></name><name><surname>Rocha-Unold</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>A</given-names></name><name><surname>Möller</surname><given-names>HJ</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI</article-title><source>Journal of Neurology</source><volume>253</volume><fpage>794</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1007/s00415-006-0120-4</pub-id><pub-id pub-id-type="pmid">16511646</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terry</surname><given-names>RD</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>Butters</surname><given-names>N</given-names></name><name><surname>DeTeresa</surname><given-names>R</given-names></name><name><surname>Hill</surname><given-names>R</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Physical basis of cognitive alterations in alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment</article-title><source>Annals of Neurology</source><volume>30</volume><fpage>572</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1002/ana.410300410</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tondelli</surname><given-names>M</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Nichelli</surname><given-names>P</given-names></name><name><surname>De Jager</surname><given-names>CA</given-names></name><name><surname>Jenkinson</surname><given-names>M</given-names></name><name><surname>Zamboni</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Structural MRI changes detectable up to ten years before clinical Alzheimer’s disease</article-title><source>Neurobiology of Aging</source><volume>33</volume><elocation-id>825</elocation-id><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2011.05.018</pub-id><pub-id pub-id-type="pmid">21782287</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsoi</surname><given-names>KKF</given-names></name><name><surname>Chan</surname><given-names>JYC</given-names></name><name><surname>Hirai</surname><given-names>HW</given-names></name><name><surname>Wong</surname><given-names>SYS</given-names></name><name><surname>Kwok</surname><given-names>TCY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cognitive tests to detect dementia: a systematic review and meta-analysis</article-title><source>JAMA Internal Medicine</source><volume>175</volume><fpage>1450</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1001/jamainternmed.2015.2152</pub-id><pub-id pub-id-type="pmid">26052687</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>JW</given-names></name><name><surname>Young</surname><given-names>AL</given-names></name><name><surname>Oxtoby</surname><given-names>NP</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Ossenkoppele</surname><given-names>R</given-names></name><name><surname>Strandberg</surname><given-names>OT</given-names></name><name><surname>La Joie</surname><given-names>R</given-names></name><name><surname>Aksman</surname><given-names>LM</given-names></name><name><surname>Grothe</surname><given-names>MJ</given-names></name><name><surname>Iturria-Medina</surname><given-names>Y</given-names></name><name><surname>Pontecorvo</surname><given-names>MJ</given-names></name><name><surname>Devous</surname><given-names>MD</given-names></name><name><surname>Rabinovici</surname><given-names>GD</given-names></name><name><surname>Alexander</surname><given-names>DC</given-names></name><name><surname>Lyoo</surname><given-names>CH</given-names></name><name><surname>Evans</surname><given-names>AC</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Four distinct trajectories of tau deposition identified in Alzheimer’s disease</article-title><source>Nature Medicine</source><volume>27</volume><fpage>871</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01309-6</pub-id><pub-id pub-id-type="pmid">33927414</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiesman</surname><given-names>AI</given-names></name><name><surname>Murman</surname><given-names>DL</given-names></name><name><surname>May</surname><given-names>PE</given-names></name><name><surname>Schantell</surname><given-names>M</given-names></name><name><surname>Losh</surname><given-names>RA</given-names></name><name><surname>Johnson</surname><given-names>HJ</given-names></name><name><surname>Willet</surname><given-names>MP</given-names></name><name><surname>Eastman</surname><given-names>JA</given-names></name><name><surname>Christopher-Hayes</surname><given-names>NJ</given-names></name><name><surname>Knott</surname><given-names>NL</given-names></name><name><surname>Houseman</surname><given-names>LL</given-names></name><name><surname>Wolfson</surname><given-names>SL</given-names></name><name><surname>Losh</surname><given-names>KL</given-names></name><name><surname>Johnson</surname><given-names>CM</given-names></name><name><surname>Wilson</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spatio-spectral relationships between pathological neural dynamics and cognitive impairment along the Alzheimer’s disease spectrum</article-title><source>Alzheimer’s &amp; Dementia</source><volume>13</volume><elocation-id>e12200</elocation-id><pub-id pub-id-type="doi">10.1002/dad2.12200</pub-id><pub-id pub-id-type="pmid">34095434</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiesman</surname><given-names>AI</given-names></name><name><surname>da Silva Castanheira</surname><given-names>J</given-names></name><name><surname>Baillet</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Stability of spectral estimates in resting-state magnetoencephalography: Recommendations for minimal data duration with neuroanatomical specificity</article-title><source>NeuroImage</source><volume>247</volume><elocation-id>118823</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2021.118823</pub-id><pub-id pub-id-type="pmid">34923132</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Brainnet viewer: a network visualization tool for human brain connectomics</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e68910</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0068910</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AL</given-names></name><name><surname>Oxtoby</surname><given-names>NP</given-names></name><name><surname>Daga</surname><given-names>P</given-names></name><name><surname>Cash</surname><given-names>DM</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Ourselin</surname><given-names>S</given-names></name><name><surname>Schott</surname><given-names>JM</given-names></name><name><surname>Alexander</surname><given-names>DC</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><year iso-8601-date="2014">2014</year><article-title>A data-driven model of biomarker changes in sporadic Alzheimer’s disease</article-title><source>Brain</source><volume>137</volume><fpage>2564</fpage><lpage>2577</lpage><pub-id pub-id-type="doi">10.1093/brain/awu176</pub-id><pub-id pub-id-type="pmid">25012224</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AL</given-names></name><name><surname>Marinescu</surname><given-names>RV</given-names></name><name><surname>Oxtoby</surname><given-names>NP</given-names></name><name><surname>Bocchetta</surname><given-names>M</given-names></name><name><surname>Yong</surname><given-names>K</given-names></name><name><surname>Firth</surname><given-names>NC</given-names></name><name><surname>Cash</surname><given-names>DM</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Dick</surname><given-names>KM</given-names></name><name><surname>Cardoso</surname><given-names>J</given-names></name><name><surname>van Swieten</surname><given-names>J</given-names></name><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Galimberti</surname><given-names>D</given-names></name><name><surname>Masellis</surname><given-names>M</given-names></name><name><surname>Tartaglia</surname><given-names>MC</given-names></name><name><surname>Rowe</surname><given-names>JB</given-names></name><name><surname>Graff</surname><given-names>C</given-names></name><name><surname>Tagliavini</surname><given-names>F</given-names></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Laforce</surname><given-names>R</given-names></name><name><surname>Finger</surname><given-names>E</given-names></name><name><surname>de Mendonça</surname><given-names>A</given-names></name><name><surname>Sorbi</surname><given-names>S</given-names></name><name><surname>Warren</surname><given-names>JD</given-names></name><name><surname>Crutch</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Ourselin</surname><given-names>S</given-names></name><name><surname>Schott</surname><given-names>JM</given-names></name><name><surname>Rohrer</surname><given-names>JD</given-names></name><name><surname>Alexander</surname><given-names>DC</given-names></name><name><surname>Andersson</surname><given-names>C</given-names></name><name><surname>Archetti</surname><given-names>S</given-names></name><name><surname>Arighi</surname><given-names>A</given-names></name><name><surname>Benussi</surname><given-names>L</given-names></name><name><surname>Binetti</surname><given-names>G</given-names></name><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Cosseddu</surname><given-names>M</given-names></name><name><surname>Fallström</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>C</given-names></name><name><surname>Fenoglio</surname><given-names>C</given-names></name><name><surname>Freedman</surname><given-names>M</given-names></name><name><surname>Fumagalli</surname><given-names>GG</given-names></name><name><surname>Gazzina</surname><given-names>S</given-names></name><name><surname>Ghidoni</surname><given-names>R</given-names></name><name><surname>Grisoli</surname><given-names>M</given-names></name><name><surname>Jelic</surname><given-names>V</given-names></name><name><surname>Jiskoot</surname><given-names>L</given-names></name><name><surname>Keren</surname><given-names>R</given-names></name><name><surname>Lombardi</surname><given-names>G</given-names></name><name><surname>Maruta</surname><given-names>C</given-names></name><name><surname>Meeter</surname><given-names>L</given-names></name><name><surname>Mead</surname><given-names>S</given-names></name><name><surname>van Minkelen</surname><given-names>R</given-names></name><name><surname>Nacmias</surname><given-names>B</given-names></name><name><surname>Öijerstedt</surname><given-names>L</given-names></name><name><surname>Padovani</surname><given-names>A</given-names></name><name><surname>Panman</surname><given-names>J</given-names></name><name><surname>Pievani</surname><given-names>M</given-names></name><name><surname>Polito</surname><given-names>C</given-names></name><name><surname>Premi</surname><given-names>E</given-names></name><name><surname>Prioni</surname><given-names>S</given-names></name><name><surname>Rademakers</surname><given-names>R</given-names></name><name><surname>Redaelli</surname><given-names>V</given-names></name><name><surname>Rogaeva</surname><given-names>E</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Rossor</surname><given-names>M</given-names></name><name><surname>Scarpini</surname><given-names>E</given-names></name><name><surname>Tang-Wai</surname><given-names>D</given-names></name><name><surname>Thonberg</surname><given-names>H</given-names></name><name><surname>Tiraboschi</surname><given-names>P</given-names></name><name><surname>Verdelho</surname><given-names>A</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Aisen</surname><given-names>P</given-names></name><name><surname>Petersen</surname><given-names>R</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Jagust</surname><given-names>W</given-names></name><name><surname>Trojanowki</surname><given-names>JQ</given-names></name><name><surname>Toga</surname><given-names>AW</given-names></name><name><surname>Beckett</surname><given-names>L</given-names></name><name><surname>Green</surname><given-names>RC</given-names></name><name><surname>Saykin</surname><given-names>AJ</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Khachaturian</surname><given-names>Z</given-names></name><name><surname>Sorensen</surname><given-names>G</given-names></name><name><surname>Kuller</surname><given-names>L</given-names></name><name><surname>Raichle</surname><given-names>M</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Fillit</surname><given-names>H</given-names></name><name><surname>Hefti</surname><given-names>F</given-names></name><name><surname>Holtzman</surname><given-names>D</given-names></name><name><surname>Mesulam</surname><given-names>MM</given-names></name><name><surname>Potter</surname><given-names>W</given-names></name><name><surname>Snyder</surname><given-names>P</given-names></name><name><surname>Schwartz</surname><given-names>A</given-names></name><name><surname>Montine</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>RG</given-names></name><name><surname>Donohue</surname><given-names>M</given-names></name><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Gessert</surname><given-names>D</given-names></name><name><surname>Sather</surname><given-names>T</given-names></name><name><surname>Jiminez</surname><given-names>G</given-names></name><name><surname>Harvey</surname><given-names>D</given-names></name><name><surname>Bernstein</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>P</given-names></name><name><surname>Schuff</surname><given-names>N</given-names></name><name><surname>Borowski</surname><given-names>B</given-names></name><name><surname>Gunter</surname><given-names>J</given-names></name><name><surname>Senjem</surname><given-names>M</given-names></name><name><surname>Vemuri</surname><given-names>P</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Kantarci</surname><given-names>K</given-names></name><name><surname>Ward</surname><given-names>C</given-names></name><name><surname>Koeppe</surname><given-names>RA</given-names></name><name><surname>Foster</surname><given-names>N</given-names></name><name><surname>Reiman</surname><given-names>EM</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Mathis</surname><given-names>C</given-names></name><name><surname>Landau</surname><given-names>S</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Householder</surname><given-names>E</given-names></name><name><surname>Taylor-Reinwald</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>V</given-names></name><name><surname>Korecka</surname><given-names>M</given-names></name><name><surname>Figurski</surname><given-names>M</given-names></name><name><surname>Crawford</surname><given-names>K</given-names></name><name><surname>Neu</surname><given-names>S</given-names></name><name><surname>Foroud</surname><given-names>TM</given-names></name><name><surname>Potkin</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Faber</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Nho</surname><given-names>K</given-names></name><name><surname>Thal</surname><given-names>L</given-names></name><name><surname>Buckholtz</surname><given-names>N</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Frank</surname><given-names>R</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name><name><surname>Quinn</surname><given-names>J</given-names></name><name><surname>Lind</surname><given-names>B</given-names></name><name><surname>Carter</surname><given-names>R</given-names></name><name><surname>Dolen</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>LS</given-names></name><name><surname>Pawluczyk</surname><given-names>S</given-names></name><name><surname>Beccera</surname><given-names>M</given-names></name><name><surname>Teodoro</surname><given-names>L</given-names></name><name><surname>Spann</surname><given-names>BM</given-names></name><name><surname>Brewer</surname><given-names>J</given-names></name><name><surname>Vanderswag</surname><given-names>H</given-names></name><name><surname>Fleisher</surname><given-names>A</given-names></name><name><surname>Heidebrink</surname><given-names>JL</given-names></name><name><surname>Lord</surname><given-names>JL</given-names></name><name><surname>Mason</surname><given-names>SS</given-names></name><name><surname>Albers</surname><given-names>CS</given-names></name><name><surname>Knopman</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Doody</surname><given-names>RS</given-names></name><name><surname>Villanueva-Meyer</surname><given-names>J</given-names></name><name><surname>Chowdhury</surname><given-names>M</given-names></name><name><surname>Rountree</surname><given-names>S</given-names></name><name><surname>Dang</surname><given-names>M</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Bell</surname><given-names>KL</given-names></name><name><surname>Ances</surname><given-names>B</given-names></name><name><surname>Carroll</surname><given-names>M</given-names></name><name><surname>Leon</surname><given-names>S</given-names></name><name><surname>Mintun</surname><given-names>MA</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Oliver</surname><given-names>A</given-names></name><name><surname>Marson</surname><given-names>D</given-names></name><name><surname>Griffith</surname><given-names>R</given-names></name><name><surname>Clark</surname><given-names>D</given-names></name><name><surname>Geldmacher</surname><given-names>D</given-names></name><name><surname>Brockington</surname><given-names>J</given-names></name><name><surname>Roberson</surname><given-names>E</given-names></name><name><surname>Grossman</surname><given-names>H</given-names></name><name><surname>Mitsis</surname><given-names>E</given-names></name><name><surname>de Toledo-Morrell</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>RC</given-names></name><name><surname>Duara</surname><given-names>R</given-names></name><name><surname>Varon</surname><given-names>D</given-names></name><name><surname>Greig</surname><given-names>MT</given-names></name><name><surname>Roberts</surname><given-names>P</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Onyike</surname><given-names>C</given-names></name><name><surname>D’Agostino</surname><given-names>D</given-names></name><name><surname>Kielb</surname><given-names>S</given-names></name><name><surname>Galvin</surname><given-names>JE</given-names></name><name><surname>Cerbone</surname><given-names>B</given-names></name><name><surname>Michel</surname><given-names>CA</given-names></name><name><surname>Rusinek</surname><given-names>H</given-names></name><name><surname>de Leon</surname><given-names>MJ</given-names></name><name><surname>Glodzik</surname><given-names>L</given-names></name><name><surname>De Santi</surname><given-names>S</given-names></name><name><surname>Doraiswamy</surname><given-names>PM</given-names></name><name><surname>Petrella</surname><given-names>JR</given-names></name><name><surname>Wong</surname><given-names>TZ</given-names></name><name><surname>Arnold</surname><given-names>SE</given-names></name><name><surname>Karlawish</surname><given-names>JH</given-names></name><name><surname>Wolk</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>CD</given-names></name><name><surname>Jicha</surname><given-names>G</given-names></name><name><surname>Hardy</surname><given-names>P</given-names></name><name><surname>Sinha</surname><given-names>P</given-names></name><name><surname>Oates</surname><given-names>E</given-names></name><name><surname>Conrad</surname><given-names>G</given-names></name><name><surname>Lopez</surname><given-names>OL</given-names></name><name><surname>Oakley</surname><given-names>M</given-names></name><name><surname>Simpson</surname><given-names>DM</given-names></name><name><surname>Porsteinsson</surname><given-names>AP</given-names></name><name><surname>Goldstein</surname><given-names>BS</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Makino</surname><given-names>KM</given-names></name><name><surname>Ismail</surname><given-names>MS</given-names></name><name><surname>Brand</surname><given-names>C</given-names></name><name><surname>Mulnard</surname><given-names>RA</given-names></name><name><surname>Thai</surname><given-names>G</given-names></name><name><surname>Mc-Adams-Ortiz</surname><given-names>C</given-names></name><name><surname>Womack</surname><given-names>K</given-names></name><name><surname>Mathews</surname><given-names>D</given-names></name><name><surname>Quiceno</surname><given-names>M</given-names></name><name><surname>Diaz-Arrastia</surname><given-names>R</given-names></name><name><surname>King</surname><given-names>R</given-names></name><name><surname>Weiner</surname><given-names>M</given-names></name><name><surname>Martin-Cook</surname><given-names>K</given-names></name><name><surname>DeVous</surname><given-names>M</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name><name><surname>Cellar</surname><given-names>JS</given-names></name><name><surname>Burns</surname><given-names>JM</given-names></name><name><surname>Anderson</surname><given-names>HS</given-names></name><name><surname>Swerdlow</surname><given-names>RH</given-names></name><name><surname>Apostolova</surname><given-names>L</given-names></name><name><surname>Tingus</surname><given-names>K</given-names></name><name><surname>Woo</surname><given-names>E</given-names></name><name><surname>Silverman</surname><given-names>DH</given-names></name><name><surname>Lu</surname><given-names>PH</given-names></name><name><surname>Bartzokis</surname><given-names>G</given-names></name><name><surname>Graff-Radford</surname><given-names>NR</given-names></name><name><surname>Parfitt</surname><given-names>F</given-names></name><name><surname>Kendall</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>H</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Hake</surname><given-names>AM</given-names></name><name><surname>Matthews</surname><given-names>BR</given-names></name><name><surname>Herring</surname><given-names>S</given-names></name><name><surname>Hunt</surname><given-names>C</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Carson</surname><given-names>RE</given-names></name><name><surname>MacAvoy</surname><given-names>MG</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Hosein</surname><given-names>C</given-names></name><name><surname>Stefanovic</surname><given-names>B</given-names></name><name><surname>Caldwell</surname><given-names>C</given-names></name><name><surname>Hsiung</surname><given-names>G-YR</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Mudge</surname><given-names>B</given-names></name><name><surname>Assaly</surname><given-names>M</given-names></name><name><surname>Kertesz</surname><given-names>A</given-names></name><name><surname>Rogers</surname><given-names>J</given-names></name><name><surname>Bernick</surname><given-names>C</given-names></name><name><surname>Munic</surname><given-names>D</given-names></name><name><surname>Kerwin</surname><given-names>D</given-names></name><name><surname>Mesulam</surname><given-names>M-M</given-names></name><name><surname>Lipowski</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>C-K</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Sadowsky</surname><given-names>C</given-names></name><name><surname>Martinez</surname><given-names>W</given-names></name><name><surname>Villena</surname><given-names>T</given-names></name><name><surname>Turner</surname><given-names>RS</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Reynolds</surname><given-names>B</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Marshall</surname><given-names>G</given-names></name><name><surname>Frey</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>B</given-names></name><name><surname>Rosen</surname><given-names>A</given-names></name><name><surname>Tinklenberg</surname><given-names>J</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Belden</surname><given-names>CM</given-names></name><name><surname>Jacobson</surname><given-names>SA</given-names></name><name><surname>Sirrel</surname><given-names>SA</given-names></name><name><surname>Kowall</surname><given-names>N</given-names></name><name><surname>Killiany</surname><given-names>R</given-names></name><name><surname>Budson</surname><given-names>AE</given-names></name><name><surname>Norbash</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>PL</given-names></name><name><surname>Allard</surname><given-names>J</given-names></name><name><surname>Lerner</surname><given-names>A</given-names></name><name><surname>Ogrocki</surname><given-names>P</given-names></name><name><surname>Hudson</surname><given-names>L</given-names></name><name><surname>Fletcher</surname><given-names>E</given-names></name><name><surname>Carmichael</surname><given-names>O</given-names></name><name><surname>Olichney</surname><given-names>J</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Kittur</surname><given-names>S</given-names></name><name><surname>Borrie</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>TY</given-names></name><name><surname>Bartha</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Asthana</surname><given-names>S</given-names></name><name><surname>Carlsson</surname><given-names>CM</given-names></name><name><surname>Potkin</surname><given-names>SG</given-names></name><name><surname>Preda</surname><given-names>A</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><name><surname>Tariot</surname><given-names>P</given-names></name><name><surname>Reeder</surname><given-names>S</given-names></name><name><surname>Bates</surname><given-names>V</given-names></name><name><surname>Capote</surname><given-names>H</given-names></name><name><surname>Rainka</surname><given-names>M</given-names></name><name><surname>Scharre</surname><given-names>DW</given-names></name><name><surname>Kataki</surname><given-names>M</given-names></name><name><surname>Adeli</surname><given-names>A</given-names></name><name><surname>Zimmerman</surname><given-names>EA</given-names></name><name><surname>Celmins</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>AD</given-names></name><name><surname>Pearlson</surname><given-names>GD</given-names></name><name><surname>Blank</surname><given-names>K</given-names></name><name><surname>Anderson</surname><given-names>K</given-names></name><name><surname>Santulli</surname><given-names>RB</given-names></name><name><surname>Kitzmiller</surname><given-names>TJ</given-names></name><name><surname>Schwartz</surname><given-names>ES</given-names></name><name><surname>Sink</surname><given-names>KM</given-names></name><name><surname>Williamson</surname><given-names>JD</given-names></name><name><surname>Garg</surname><given-names>P</given-names></name><name><surname>Watkins</surname><given-names>F</given-names></name><name><surname>Ott</surname><given-names>BR</given-names></name><name><surname>Querfurth</surname><given-names>H</given-names></name><name><surname>Tremont</surname><given-names>G</given-names></name><name><surname>Salloway</surname><given-names>S</given-names></name><name><surname>Malloy</surname><given-names>P</given-names></name><name><surname>Correia</surname><given-names>S</given-names></name><name><surname>Rosen</surname><given-names>HJ</given-names></name><name><surname>Miller</surname><given-names>BL</given-names></name><name><surname>Mintzer</surname><given-names>J</given-names></name><name><surname>Spicer</surname><given-names>K</given-names></name><name><surname>Bachman</surname><given-names>D</given-names></name><name><surname>Pasternak</surname><given-names>S</given-names></name><name><surname>Rachinsky</surname><given-names>I</given-names></name><name><surname>Drost</surname><given-names>D</given-names></name><name><surname>Pomara</surname><given-names>N</given-names></name><name><surname>Hernando</surname><given-names>R</given-names></name><name><surname>Sarrael</surname><given-names>A</given-names></name><name><surname>Schultz</surname><given-names>SK</given-names></name><name><surname>Ponto</surname><given-names>LLB</given-names></name><name><surname>Shim</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>KE</given-names></name><name><surname>Relkin</surname><given-names>N</given-names></name><name><surname>Chaing</surname><given-names>G</given-names></name><name><surname>Raudin</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Fargher</surname><given-names>K</given-names></name><name><surname>Raj</surname><given-names>BA</given-names></name><name><surname>Neylan</surname><given-names>T</given-names></name><name><surname>Grafman</surname><given-names>J</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>R</given-names></name><name><surname>Hayes</surname><given-names>J</given-names></name><name><surname>Finley</surname><given-names>S</given-names></name><name><surname>Friedl</surname><given-names>K</given-names></name><name><surname>Fleischman</surname><given-names>D</given-names></name><name><surname>Arfanakis</surname><given-names>K</given-names></name><name><surname>James</surname><given-names>O</given-names></name><name><surname>Massoglia</surname><given-names>D</given-names></name><name><surname>Fruehling</surname><given-names>JJ</given-names></name><name><surname>Harding</surname><given-names>S</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Petrie</surname><given-names>EC</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Yesavage</surname><given-names>JA</given-names></name><name><surname>Taylor</surname><given-names>JL</given-names></name><name><surname>Furst</surname><given-names>AJ</given-names></name><collab>The Genetic FTD Initiative (GENFI)</collab><collab>The Alzheimer’s Disease Neuroimaging Initiative (ADNI)</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4273</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-05892-0</pub-id><pub-id pub-id-type="pmid">30323170</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>McInnes</surname><given-names>J</given-names></name><name><surname>Wierda</surname><given-names>K</given-names></name><name><surname>Holt</surname><given-names>M</given-names></name><name><surname>Herrmann</surname><given-names>AG</given-names></name><name><surname>Jackson</surname><given-names>RJ</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Swerts</surname><given-names>J</given-names></name><name><surname>Beyens</surname><given-names>J</given-names></name><name><surname>Miskiewicz</surname><given-names>K</given-names></name><name><surname>Vilain</surname><given-names>S</given-names></name><name><surname>Dewachter</surname><given-names>I</given-names></name><name><surname>Moechars</surname><given-names>D</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Spires-Jones</surname><given-names>TL</given-names></name><name><surname>De Wit</surname><given-names>J</given-names></name><name><surname>Verstreken</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Tau association with synaptic vesicles causes presynaptic dysfunction</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>15295</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms15295</pub-id><pub-id pub-id-type="pmid">28492240</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91044.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Herrmann</surname><given-names>Björn</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Baycrest</institution><country>Canada</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This work presents <bold>important</bold> findings for the field of Alzheimer's disease, especially for the electrophysiology subfield, by investigating the temporal evolution of different disease stages typically reported using M/EEG markers of resting-state brain activity. The evidence supporting the conclusions is <bold>convincing</bold> and the methodology as well as the descriptions of the processes are of high quality, although a separation of individuals who are biomarker positive versus negative would have strengthened the results and conclusions of the study.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91044.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The authors aimed to infer the trajectories of long range and local neuronal synchrony across the Alzheimer's disease continuum, relative to neurodegeneration and cognitive decline. The trajectories are inferred using event-based models, which infer a set of data-driven disease stages from a given dataset. The authors develop an adapted event-based modelling approach, in which they characterise each stage as a particular biomarker increasing by a particular z-score deviation from controls. Fitting infers the optimal set of z-scores to use for each biomarker and the order in which each biomarker reaches each z-score. The authors apply this approach to data from 148 individuals (70 cognitively unimpaired older adults and 78 individual with mild cognitive impairment or Alzheimer's disease), identifying trajectories in which long-range (amplitude-envolope correlation) and local (regional spectral power) neuronal synchrony in the alpha and beta bands becomes abnormal prior to neurodegeneration (measured as the volume of the parahippocampal gyrus) and cognitive decline (measured using the mini-mental state examination).</p><p>Strengths:</p><p>- The main strength is that the authors assess two models. In the first they derive a staging system based only on the volume of the parahippocampal gyrus and mini-mental state examination score. They then investigate how neuronal synchrony metrics change compared to this staging system. In the second they derive a staging system that also includes an average (combined long-range and local) neuronal synchrony metric and investigate how long-range and local synchrony metrics change relative to this staging system. This is a strength as the first model provides confidence that there is not overfitting to the neuronal synchrony data, and the second provides more detailed insights into the dynamics of the early neuronal synchrony changes.</p><p>- Another strength is that the authors automatically infer the optimal z-scores to choose, rather than having to pre-select them manually, as in previous approaches.</p><p>Weaknesses:</p><p>- The authors do not have a dataset for external validation.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91044.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary: This work presented by Kudo and colleagues is of great importance to strengthen our understanding of electrophysiological changes in the course of AD. Although the main conclusions regarding functional connectivity and spectral power change through the course of the disease are not new and have been largely studied and theorised on, this article offers an innovative approach that certainly consolidates previous knowledge on the topic. Not only that, this article also broadens our knowledge presenting useful and important details on the specificity of frequency and cortical distribution of these early alterations. The main take-home message of this work is the early disruption of electrophysiological signatures that precedes detectable alterations in other more commonly used pathology markers (i.e. gray matter atrophy and cognitive impairment). More specifically, these signatures include long-range connectivity in the alpha and beta bands, and local synchrony (spectral power) in the same frequency bands.</p><p>Strengths: The present work has some major strengths that make it paramount for the advance of our understanding of AD electrophysiology. It is a very well written manuscript that, despite the complexity of the analyses employed, runs the reader through the different steps of the analysis in a pedagogic and clever way, making the points raised by the results easy to grasp. The methodology itself is carefully chosen and appropriate to the nature of the question posed by the researchers, as event-based models are well-suited for cross-sectional data.</p><p>The quality of the figures is outstanding; not only are they aesthetic but, more importantly, the figures convey information exceptionally well and facilitate comprehension of the main results.</p><p>The conclusions of the paper are, in general, well described and discussed, and consider the state-of-the-art works of AD electrophysiology. Furthermore, even though the conclusions themselves are not groundbreaking at all (synaptic damage preceding structural and cognitive impairment is one of the epitomes of the pathological cascading model proposed by Jack in 2010), this article is innovative and groundbreaking in the way they address with clever analyses in a relatively large sample for neuroimaging standards.</p><p>Weaknesses: The authors increased the clarity of sample description after revisions (particularly control group characterization). However, even though it is true that a certain percentage of AB positivity is to be expected amongst cognitively healthy individuals, that doesn´t discard they are not expressing preclinical AD to some extent. I still feel that including only biomarker negative participants in the control group would increase the quality of the work. However, the sample is relatively well characterized as a whole and the results are interesting and in line with previous literature, thus limiting the apparent impact of these possible confounds.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.91044.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kudo</surname><given-names>Kiwamu</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Ranasinghe</surname><given-names>Kamalini</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Morise</surname><given-names>Hirofumi</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Syed</surname><given-names>Faatimah</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Sekihara</surname><given-names>Kensuke</given-names></name><role specific-use="author">Author</role><aff><institution>Signal Analysis Inc.</institution><addr-line><named-content content-type="city">Hachioji</named-content></addr-line><country>Japan</country></aff></contrib><contrib contrib-type="author"><name><surname>Rankin</surname><given-names>Katherine P</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Bruce L</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kramer</surname><given-names>Joel</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Rabinovici</surname><given-names>Gil</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Vossel</surname><given-names>Keith</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, Los Angeles</institution><addr-line><named-content content-type="city">Los Angeles</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kirsch</surname><given-names>Heidi E</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Nagarajan</surname><given-names>Srikantan</given-names></name><role specific-use="author">Author</role><aff><institution>University of California, San Francisco</institution><addr-line><named-content content-type="city">San Francisco</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>eLife assessment</bold></p><p>This work presents important findings for the field of Alzheimer's disease, especially for the electrophysiology subfield, by investigating the temporal evolution of different disease stages typically reported using M/EEG markers of resting-state brain activity. The evidence supporting the conclusions is solid and the methodology as well as the descriptions of the processes are of high quality, although a separation of individuals who are biomarker positive versus negative would have strengthened the interpretability of the results and the conclusions of the study.</p></disp-quote><p>Response: Thank you for the positive assessment of the paper.</p><disp-quote content-type="editor-comment"><p><bold>Public Reviews:</bold></p><p><bold>Reviewer #1 (Public Review):</bold></p><p>Summary:</p><p>The authors aimed to infer the trajectories of long range and local neuronal synchrony across the Alzheimer's disease continuum, relative to neurodegeneration and cognitive decline. The trajectories are inferred using event-based models, which infer a set of data-driven disease stages from a given dataset. The authors develop an adapted event-based modelling approach, in which they characterise each stage as a particular biomarker increasing by a particular z-score deviation from controls. Fitting infers the optimal set of z-scores to use for each biomarker and the order in which each biomarker reaches each z-score. The authors apply this approach to data from 148 individuals (70 cognitively unimpaired older adults and 78 individual with mild cognitive impairment or Alzheimer's disease), identifying trajectories in which long-range (amplitude-envolope correlation) and local (regional spectral power) neuronal synchrony in the alpha and beta bands becomes abnormal prior to neurodegeneration (measured as the volume of the parahippocampal gyrus) and cognitive decline (measured using the mini-mental state examination).</p><p>Strengths:</p><list list-type="bullet"><list-item><p>The main strength is that the authors assess two models. In the first they derive a staging system based only on the volume of the parahippocampal gyrus and mini-mental state examination score. They then investigate how neuronal synchrony metrics change compared to this staging system. In the second they derive a staging system that also includes an average (combined long-range and local) neuronal synchrony metric and investigate how long-range and local synchrony metrics change relative to this staging system. This is a strength as the first model provides confidence that there is not overfitting to the neuronal synchrony data, and the second provides more detailed insights into the dynamics of the early neuronal synchrony changes.</p></list-item></list><list list-type="bullet"><list-item><p>Another strength is that the authors automatically infer the optimal z-scores to choose, rather than having to pre-select them manually, as in previous approaches.</p></list-item></list></disp-quote><p>Response: Thank you for the positive comments and a succinct summary of the paper and its strengths.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><list list-type="bullet"><list-item><p>The dataset is small and no external validation is performed.</p></list-item></list></disp-quote><p>Response: We agree that future validation studies of the predictions are necessary. We now include the related sentences in the last paragraph of the limitations section in the revised manuscript.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>A high proportion of the data is from controls (nearly 50%) with no biomarker evidence of Alzheimer's disease, and so the changes may be driven by aging or other non-Alzheimer's effects.</p></list-item></list></disp-quote><p>Response: We would like to clarify that the z-scores of the metrics used in the EBMs were computed using age-adjusted values. All our controls were recruited from an ongoing longitudinal study of healthy aging. Amongst the 70 controls, 39 have confirmed A-beta negative PET scans and 8 were confirmed A-beta positive PET scans, and in the rest of the 23 we do not have any biomarker data available. However, in all the controls, we have conducted comprehensive neuropsychological assessment (see Appendix 1—table 1 in the revised supplementary file) and based on this data we can be quite confident about their lack of clinical deficits, and we have a very high degree of confidence that none of the controls have any neurodegeneration (AD-related or otherwise). Consistent with this assessment, in our EBM analyses, most of the control participants were indeed categorized to the preclinical stages.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Inferring the optimal z-scores is a strength, however as different sets of z-scores are allowed per biomarker, there is a concern that the changes reflected are mainly driven by the choice of z-score, rather than the markers themselves (e.g. if lower z-scores are selected for one marker than another, then changes in that marker will appear to be detected earlier, even if both markers change at the same time).</p></list-item></list></disp-quote><p>Response: Indeed, the biomarker sequence depends on the choice of the z-scores per biomarker. However, please note that our choice of z-scores is based on maximizing the sequence likelihood. Therefore, other values of the z-scores will have by construction a smaller likelihood of sequence occurrence compared to the results shown.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>In equation 2 it is unclear why the gaussian is measured based on a sum over I. The more obvious choice would be to use a multivariate gaussian with no covariance, which would mean taking the product rather than the sum over I.</p></list-item></list></disp-quote><p>Response: We thank the reviewer for pointing this out and we now clarify this point. In this revision, we do not use the term ‘multivariate’. Indeed, the model likelihood assumes independence for each metric’s priors, and hence is the product of each metric’s univariate gaussian probability distribution. This can be seen in equations 1 and 2 of the revision manuscript (Section titled “Event-based sequencing modeling’). The assumption about independent priors is similar to the one used in the original event-based model (see equation (2) in A .L. Young et al., Nature Comm. 9.1 (2018): 4273).</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>In the original event-based model, k is a hidden variable. Presumably that is also the case here, however the notation k=stage(j) makes it seem like each subject is assigned a stage during the sequence optimisation.</p></list-item></list></disp-quote><p>Response: We would like to clarify that the posterior probability of each stage for every subject is estimated during the sequence optimization. To clarify the notation, we have now deleted the term “stage” and use “tj” to denote stages for each subject j. The sequence optimization was performed with the assumption of a uniform prior distribution p(tj=k) = 1/(N+1) for each stage k. Then, the posterior probability p(tj=k|Zj,S), i.e., the probability that subject j belongs to stage k, given the metrics and the sequence, was computed during the sequence optimization procedure.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Typically for event-based modeling, positional variance diagrams are created from the markov chain monte carlo samples of the event sequence, enabling visualisation of the uncertainty in the sequence, but these are not included in the study.</p></list-item></list></disp-quote><p>Response: In the revised supplementary file, we have now included positional uncertainty diagrams for the optimal set of z-score events that were created from 50,000 MCMC samples. Please see Appendix 1—ﬁgure 2 for the AC-EBM and Appendix 1—ﬁgure 9 for the SAC-EBMs.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Many of the figures in the manuscript (e.g. Figure 1E/G, Figure 2A/B, Figure 3A/B/E/F/I/J, Figure 4 A/B/E/F/I/J) are based on averages in both the x and the y axis. In the x dimension, individuals have a weighted contribution to the value on the y axis, depending on their stage probability. In the y dimension, the values are averages across those individuals, and the error bars represent the standard error rather than the standard deviation. Whilst the trajectories themselves are interesting, they may not be discriminative at the individual level and may be more heterogeneous than it appears.</p></list-item></list></disp-quote><p>Response: In the current study, the predictions of trajectories are intended at the cohort level. Individual level investigations will be the topic of future investigations.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>The bootstrapped statistical analyses comparing metrics between the stages do not consider the variability in the sequence.</p></list-item></list></disp-quote><p>Response: Please see the response above. The positional uncertainty diagrams are included in the revised supplementary file.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Summary:</p><p>This work presented by Kudo and colleagues is of great importance to strengthen our understanding of electrophysiological changes in the course of AD. Although the main conclusions regarding functional connectivity and spectral power change through the course of the disease are not new and have been largely studied and theorised on, this article offers an innovative approach that certainly consolidates previous knowledge on the topic. Not only that, this article also broadens our knowledge presenting useful and important details on the specificity of frequency and cortical distribution of these early alterations. The main take-home message of this work is the early disruption of electrophysiological signatures that precedes detectable alterations in other more commonly used pathology markers (i.e. gray matter atrophy and cognitive impairment). More specifically, these signatures include long-range connectivity in the alpha and beta bands, and local synchrony (spectral power) in the same frequency bands.</p></disp-quote><p>Response: Thank you for the positive comments and for providing a nice succinct summary.</p><disp-quote content-type="editor-comment"><p>Strengths:</p><p>The present work has some major strengths that make it paramount for the advance of our understanding of AD electrophysiology. It is a very well written manuscript that, despite the complexity of the analyses employed, runs the reader through the different steps of the analysis in a pedagogic and clever way, making the points raised by the results easy to grasp. The methodology itself is carefully chosen and appropriate to the nature of the question posed by the researchers, as event-based models are well-suited for cross-sectional data.</p><p>The quality of the figures is outstanding; not only are they aesthetic but, more importantly, the figures convey information exceptionally well and facilitate comprehension of the main results.</p><p>The conclusions of the paper are, in general, well described and discussed, and consider the state-of-the-art works of AD electrophysiology. Furthermore, even though the conclusions themselves are not groundbreaking at all (synaptic damage preceding structural and cognitive impairment is one of the epitomes of the pathological cascading model proposed by Jack in 2010), this article is innovative and groundbreaking in the way they address with clever analyses in a relatively large sample for neuroimaging standards.</p></disp-quote><p>Response: Thank you for the positive comments of the strengths of the paper.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The main limitation of the work revolves around sample definition and inclusion criteria that are somewhat confusing obscuring some of the points of the analyses. Firstly it is not clear why the purely clinical approach is employed to diagnose the &quot;probable Alzheimer´s Disease&quot; for the 78 participants in the &quot;AD group&quot;. In the same paragraph, it is stated that 67 out of the 78 participants show biomarker positivity, thus allowing a more biologically guided diagnosis that is preferred according to current NIA-AA criteria. This would avoid highly possible mixing of different subtypes of dementia etiologies. One might wonder, why would those 11 participants be included if we have strong indications that their symptoms are not due to AD? Furthermore, the real pathological status of the control group is somewhat questionable. The authors do not specify whether common AD biomarkers are available for this subgroup. In that case, it would have highly increased the clarity and interpretability of the results if this group was subdivided in a preclinical and completely healthy control group. This would be particularly interesting since a significant proportion of the control group is labeled as belonging to stages 2,3,4 (MCI) and even 5 (mild dementia). This raises the question of whether these participants are true healthy controls mislabeled by the EBM model, or actual cognitive controls with actual underlying AD pathology well identified by the model proposed.</p></disp-quote><p>Response: Please see responses above to a similar comment from R1. To clarify, all our controls were recruited from an ongoing longitudinal study of healthy aging. Amongst the 70 controls, 39 have confirmed A-beta negative PET scans and 8 were confirmed A-beta positive PET scans, and in the rest of the 23 we do not have any biomarker data available. The biomarker positivity rates in our control cohort are completely consistent with the prevalence of A-beta positivity in cognitively healthy individuals and are within a normal biological continuum for amyloid beta (Jansen WJ et al. 2015). In all the controls, we have conducted comprehensive neuropsychological assessment (see Appendix 1—table 1 in the revised supplementary file) and based on this data we can be quite confident about their lack of clinical deficits, and we have a high degree of confidence that none of the controls have any neurodegeneration (AD-related or otherwise). We include these details in the revision (see the revised ‘Participants’ section in the Materials and methods.).</p><p>Jansen WJ et al., 2015 JAMA; 667 313(19):1924-1938.</p><disp-quote content-type="editor-comment"><p>On this note, Figure 2 (C and D) and Figure 3 (C, G and K) show a cortical surface depicting the mean difference of each stage vs the control group, which again, is formed by subjects that can be included (and in fact, are included) in all those stages, obscuring the meaning and interpretability of these cortical distributions.</p></disp-quote><p>Response: We would like to clarify that these figures depict the regional maps of each metric for each stage of AD progression, not the contrast against a control group.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Recommendations For The Authors):</bold></p><list list-type="bullet"><list-item><p>If possible, perform independent validation of the results.</p></list-item></list></disp-quote><p>Response: This is something we indeed intend to examine in our future investigations.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Repeat the analysis in the subset of individuals that are amyloid positive.</p></list-item></list></disp-quote><p>Response: Amongst the 78 AD patients, 20 had autopsy confirmed AD neuropathology, an additional 41 patients had molecular pathology identified by Abeta-PET, and another additional 9 had fluid biomarker (CSF) confirmation of amyloid and tau levels consistent with AD diagnosis. Eight remaining patients had a diagnosis of AD with high certainty, based on clinical presentation, neurological assessment, and cortical atrophy on MRI. Given that there are only eight patients who had clinical diagnosis of AD (with no biomarkers), and the comprehensive clinical characterization of all the AD patients in our cohort (Appendix 1—table 1), we do not believe that any subgroup analysis is warranted.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>When inferring the optimal z-scores, select the same set of z-scores per biomarker, or include diagrams of stage vs z-score that include all of the markers so that it is easy to see how one marker changes relative to the others (overlay Figure 1G on Figure 2A and 2B).</p></list-item></list></disp-quote><p>Response: How the neural synchrony metrics, PHG volume and MMSE scores change relative to each other is exactly what we show in Figures 3 B/F/J and 4 B/F/J. Since each EBM model optimizes the z-score thresholds, sequence likelihood and posterior probability of each stage for each subject, the EBM framework provides the most likely estimate for each metric at every stage. Therefore, the SAC-EBM model gives the most accurate description of the relative differences in these metrics over the AD progression stages. The reviewer’s suggestion to overlay Figure 1G (now figure 1F, based on optimized z-scores for PHG volume and MMSE scores) on Figures 2A and 2B will be inaccurate, as the neural synchrony measures plotted in figures 2A and 2B are not for optimized z-scores.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Change equation 2 to use a multivariate gaussian.</p></list-item></list></disp-quote><p>Response: We now clarify that we use a factorized multivariate form that reflects independent priors for each metric which are Gaussian.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Clarify whether k is a hidden variable and possibly change the notation.</p></list-item></list></disp-quote><p>Response: We now clarify that in our notation, k is a label for the stage [k=1,..,7 (when I=2) or k=1,...,10 (when I = 3)] and is indeed a hidden variable and not observed (but inferred from the EBM). Specifically, the posterior probability for each subject j belonging to stage k was estimated as part of the sequence optimization procedure.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Generate positional variance diagrams of the MCMC samples.</p></list-item></list></disp-quote><p>Response: We are doing the MCMC to obtain the most likely sequence. We have now included positional variance diagrams of the optimal set of z-score events in Appendix 1—ﬁgure 2 and Appendix 1—ﬁgure 9 in the revised supplementary file.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>It would be interesting to study whether the stages are predictive of conversion or look at longitudinal data, if available.</p></list-item></list></disp-quote><p>Response: This is something we indeed intend to examine in our future investigations.</p><disp-quote content-type="editor-comment"><list list-type="bullet"><list-item><p>Also look at statistics across MCMC samples of the sequence.</p></list-item></list></disp-quote><p>Response: Thank you for this suggestion. In the Appendix 1—ﬁgure 10, we now include an example of the MCMC samples for an SAC-EBM including the alpha-band AEC. We then derived the positional variances for each metric that are now shown in Appendix 1—ﬁgure 2 and Appendix 1—ﬁgure 9.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Some really minor changes are suggested on two specific points that somewhat confused me as a reader and got me stuck in the reading process to try to get the meaning of what I was seeing/reading:</p><p>1. It is not specified (or at least I was unable to find it) what are you comparing exactly for the group comparison in the long-range synchrony metric (AEC) before creating your scalar metric. Are you comparing individual links (in which case you would have 93 link values for each ROI to compare)? Or are you comparing the strength for each ROI (thus, one value -the individual links sum- for each ROI)? I guess it should be the latter for what I see in the figures but it could be useful to specify it.</p></disp-quote><p>Response: The reviewer is correct. We compare the strength of each ROI, i.e., averaging over edges of the symmetric AEC matrix of functional connectivity. We now clarify this in the Amplitude-envelope correlation section and the caption of the revised Appendix 1—ﬁgure 6.</p><disp-quote content-type="editor-comment"><p>1. In Figure 1 (which, by the way, is exceptionally aesthetic, congratulations for that!) I got stuck for a relatively long time in a really small detail and I am not completely sure if I came to the right conclusion. It is regarding the X axis of the histograms in panels B and D. They are expressed as &quot;PHG volume loss&quot; and &quot;MMSE decline&quot;. So I supposed those histograms were showing some kind of subtraction, (maybe from stage X to stage Y, or from group X to group Y). I was trying to understand the histogram and rereading methods to see if I overlooked any description of that graphic and then just realized they might be just the Z-score itself for each group (control and AD) with respect to the whole population. If that is the case I would suggest changing the X-label to &quot;PHG z-score&quot; and &quot;MMSE z-score&quot; avoiding the reference to &quot;loss and &quot;decline&quot; as they are just reflecting the direct transformation to z-score.</p></disp-quote><p>Response: Thank you. We would like to clarify that the z-score for PHG volume and MMSE scores were sign-inverted so that higher values denote “PHG Volume loss” and “MMSE decline”, respectively. We now clarify this point in the revised text and legend for the revised figure 1.</p><disp-quote content-type="editor-comment"><p>Lastly, regarding the point I raised in the limitations section of the public review, I understand it might fall out of the scope of eLife reviewing process as it would require a more extensive change of the current manuscript, which is great as it is. But as a reader and researcher in the field, I would have recommended using biomarkers to divide the control group (if available) thus including in the models only those belonging to the AD continuum according to their biomarker status, and leaving those control without any biomarker positivity as the reference group for the figures I mention in that section (those showing differences for each stage in the cortical surface with respect to the control group).</p></disp-quote><p>Response: Please see a similar comment from R1. Amongst the 70 controls, 39 have confirmed A-beta negative PET scans and only 8 were confirmed A-beta positive PET scans, and in the rest of the 23 we do not have any biomarker data available. In all the controls, we have conducted comprehensive neuropsychological assessment (see Appendix 1—table 1 in the revised supplementary file) and based on this data we can be quite confident about their lack of clinical deficits, and we have a high degree of confidence that none of the controls have any neurodegeneration (AD-related or otherwise). Since only 8 participants were confirmed as amyloid positive in the control group and this sample size is small, we do not conduct this recommended re-analysis in this manuscript.</p></body></sub-article></article>